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Abstract 
The family of pentameric ligand-gated ion channels participates in the fast signal 
transmission at chemical synapses in the central nervous system and at neuromuscular 
junctions. All members of the family are pentamers, formed by either identical or 
homologous subunits. Each subunit consists of an N-terminal extracellular ligand-
binding domain and a transmembrane domain of four α-helices. The protein scaffold 
allows specific binding of small molecules, called neurotransmitters. Their binding to the 
receptor stabilizes a conformation with an aqueous pore in the center of the pentamer. 
This ion permeation path is selective for either cations, as in acetylcholine or serotonin 
receptors, or for anions, as in glycine and GABA receptors. The membrane potential is 
depolarized by cation selective channels and hyperpolarized by anion selective 
channels. Several diseases are known to be related to the dysfunction of pLGICs, as 
Alzheimer’s disease, epilepsy or schizophrenia. The family of pLGIC has been studied 
since the middle of the last century and their function and pharmacology is thus well 
understood. These studies led to the discovery of a variety of drugs, which target 
pLGICs, not only to treat the mentioned diseases, as some of them are widely used as 
tranquilizers, anesthetics or for smoking cessation. 
In contrast to the wealth of biochemical data that was collected over decades, structural 
information clarifying the underlying molecular mechanisms of the function of pLGICs is 
only available since ten years. The first insights at high resolution came from the 
structures of the acetylcholine binding proteins, small soluble proteins homologous to 
the extracellular domain of the acetylcholine receptor. At the same time, cryo-electron 
microscopy studies have provided a structural model of the full length acetylcholine 
receptor at comparably low resolution. These structures have clarified the overall 
topology of this receptor family and the mechanism of agonist and antagonist binding. 
The first high resolution structures of full-length receptors were obtained from the 
prokaryotic homologues ELIC and GLIC, which were determined by X-ray 
crystallography in two different functional states. GLIC is unusual in the family of 
pLGICs since it is activated by protons, whereas ELIC is a ligand-gated ion channel. 
However, since the physiological function of ELIC and thus the nature of activating 
ligands were unknown, its use as model system for mechanistic studies was limited. 
In my PhD studies, I have identified a set of small molecules, which are capable of 
activating ELIC. These molecules are linear primary amines and include the 
neurotransmitter GABA. The initial biophysical characterization of ELIC by 
electrophysiology revealed a complex functional behavior that resembles eukaryotic 
receptors. The ligand recognition site in ELIC is similar to glycine and GABA receptors 
but its cation selectivity is a hallmark of acetylcholine and serotonin receptors. In the 
course of the electrophysiological experiments, a strong inhibitory effect of divalent 
cations on agonist induced currents was observed. A thorough mechanistic 
investigation of this effect by X-ray crystallography and electrophysiology has allowed 
the identification of five equivalent binding sites in the pentamer, responsible for the 
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observed allosteric inhibition of ELIC by divalent cations. Our study demonstrates that 
divalent cations act by reducing the efficacy of channel opening by a mechanism that is 
also found in eukaryotic receptors. 
In combination with the previously determined crystal structure, the work of my PhD 
thesis has thus provided first insights into the activation and inhibition of ELIC and has 
established a model system to study the detailed molecular mechanisms underlying the 
function of pentameric ligand-gated ion channels. 
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Zusammenfassung 
Die Familie der pentameren ligandengesteuerten Ionenkanäle (pLGIC) ermöglicht die 
schnelle Signalübertragung an chemischen Synapsen im zentralen Nervensystem und 
an neuromuskulären Übergängen. Alle Mitglieder dieser Familie besitzen eine 
pentamere Struktur, die sich aus fünf identischen oder homologen Untereinheiten 
zusammensetzt. Jede Untereinheit besteht aus einer N-terminalen extrazellulären 
Ligandenbindungsdomäne und einer Transmembrandomäne, die aus vier α-Helices 
aufgebaut ist. Das Proteingerüst ermöglicht die Bindung spezifischer kleiner Moleküle, 
sogenannte Neurotransmitter. Die Bindung dieser Neurotransmitter stabilisiert den 
Rezeptor in einer Konformation mit einer wässrigen Pore im Zentrum des Pentamers. 
Dieser Durchgang für Ionen ist entweder selektiv für Kationen, wie im Acetylcholin- 
oder Serotoninrezeptor, oder für Anionen, wie im GABA oder Glycinrezeptor. Das 
Membranpotenzial wird durch kationenselektive Kanäle depolarisiert, durch 
anionenselektive Kanäle jedoch hyperpolarisiert. Dies führt dann zu einem erregenden, 
respektive zu einem inhibierenden Signal am Neuron. Diverse Krankheiten werden mit 
einer Fehlfunktion dieser Rezeptoren in Verbindung gebracht, wie Alzheimer, Epilepsie 
oder Schizophrenie. Die Funktion und die Pharmakologie der pLGIC sind sehr gut 
verstanden, da diese Familie schon seit der Mitte des letzten Jahrhunderts erforscht 
wird. Verschiedenste Medikamente, die mit pLGIC interagieren, wurden entdeckt und 
deren Einsatz erstreckt sich über die Behandlung der genannten Krankheiten hinaus 
und sie werden als Beruhigungsmittel, in der Anästhesie und der Therapie von 
Rauchern eigesetzt. 
Im Gegensatz zu der Fülle von biochemischen Daten, die über Jahrzehnte 
zusammengetragen wurden, sind Informationen über die Struktur dieser Rezeptoren, 
die einen Schluss über die grundlegenden molekularen Mechanismen zulassen, erst 
seit ungefähr zehn Jahren erhältlich. Die ersten Strukturen waren von Acetylcholin-
bindenden Proteinen, kleinen löslichen Proteinen die der extrazellulären Domäne des 
Acetylcholinrezeptors entsprechen. Zur gleichen Zeit folgte die erste Struktur eines 
ganzen Acetylcholinrezeptors, welche durch Kryo-Elektronenmikroskopie bei 
vergleichsweise niedriger Auslösung erreicht wurde. Diese ersten Strukturen erklärten 
sowohl die Architektur dieser Rezeptoren als auch die Mechanismen der Agonist- und 
Antagonistbindung. Die ersten hochaufgelösten Strukturen von kompletten Rezeptoren 
wurden mit den prokaryotischen Homologen ELIC und GLIC erreicht, die mit Hilfe der 
Röntgenkristallographie in zwei verschiedenen funktionellen Zuständen ermittelt 
wurden. GLIC ist ungewöhnlich in dieser Familie, da es sich um einen 
protonengesteuerten Ionenkanal handelt, wohingegen ELIC ein ligandengesteuerter 
Ionenkanal ist. Jedoch war dessen physiologische Funktion als auch die Art der 
aktivierenden Liganden unbekannt. Deshalb war der Nutzen als Modellsystem für 
mechanistische Studien trotz der bekannten Struktur begrenzt. 
In meiner Doktorarbeit habe ich einen Satz von Molekülen identifiziert welche ELIC 
aktivieren können. Es handelt sich ausschliesslich um lineare primäre Amine, darunter 
  
VIII 
auch der Neurotransmitter GABA. Die erste biophysikalische Charakterisierung von 
ELIC durch Elektrophysiologie zeigte eine komplexe Funktion mit einer starken 
Ähnlichkeit zu den eukaryotischen Rezeptoren. Obwohl die Ligandenbindungstasche in 
ELIC den GABA- und Glycinrezeptoren ähnelt, ist die Selektivität von ELIC für Kationen 
jedoch eine Eigenschaft der Acetylcholin- und Serotoninrezeptoren. Im Verlaufe der 
elekrophysiologischen Experimente wurde ein starker inhibierender Effekt von 
divalenten Kationen auf die auf ELIC zurückzuführenden Ströme beobachtet. Eine 
gründliche Untersuchung dieses Effekts mit Röntgenkristallographie und 
Elektrophysiologie erlaubte die Identifizierung von fünf äquivalenten Bindungsstellen im 
Pentamer, welche für die allosterische Inhibition von ELIC durch divalente Kationen 
verantwortlich sind. Unsere Studie zeigt, dass die divalenten Kationen eine 
Verringerung der Effektivität der Kanalöffnung verursachen und dass der zugrunde 
liegende Wirkungsmechanismus auch in eukaryotischen Rezeptoren vorkommt. 
Zusammen mit der vorgängig bestimmten Kristallstruktur hat meine Doktorarbeit erste 
Einsichten in die Aktivierung und Inhibition von ELIC verschafft und ein Modellsystem 
etabliert um die molekularen Mechanismen zu studieren, die der Funktion der 
pentameren ligandengesteuerten Ionenkanäle zugrunde liegen. 
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Introduction 
Ligand gated ion channels 
Certain families of ligand gated ion channels (LGIC) act as ionotropic receptors for 
neurotransmitters. These integral membrane proteins form ion-selective pores across 
the plasma membrane that can be controlled by ligands. At chemical synapses in the 
nervous system, neurotransmitters are released into the synaptic cleft, where they 
bind to a specific site of a LGIC. Ligand binding triggers a conformational change, 
which opens an ion conduction pore. This pore allows selected ions to flow passively 
along their electrochemical gradient. The process of neurotransmitter binding and 
gating is very fast. It occurs in the millisecond time scale, which is required for fast 
signaling at chemical synapses in the central nervous system and at neuromuscular 
junctions. 
There are three different families of LGIC forming neurotransmitter receptors. The 
first family is formed by the ionotropic glutamate receptors (NMDA and AMPA 
receptors), the second contains nucleotide gated ion channels (P2X receptors) and 
the third consists of the pentameric ligand gated ion channels (pLGICs or cys-loop 
receptors). 
The family of pLGICs is quite diverse and further divided in exitory and inhibitory 
receptors. The exitory pLGICs are Acetylcholine receptors (AChR), Serotonin 
receptors (5HT3R) and the recently discovered Zinc-activated channels (ZAC). They 
are cation selective and their activation leads to the depolarization of the cell, thereby 
triggering further downstream signaling. 
Inhibitory pLGICs are gamma-amino-butyric acid receptors (GABAAR and GABACR) 
and glycine receptors (GlyR). Besides these large receptor subfamilies, certain 
glutamate and serotonin activated inhibitory pLGICs are found in invertebrates. In 
contrast to the exitory receptors, inhibitory receptors are anion selective and their 
activation leads to a hyperpolarization of the cell preventing further downstream 
signaling. pLGICs are the only currently known family of ion channels that contains 
both cation and anion selective members. Their importance is also underlined by the 
fact that glycine and GABA are the main inhibitory neurotransmitters in the central 
nervous system. 
The diversity of the family is further increased by multiple genes, which code for 
different subunits. In the assembled receptor, the subunits are arranged as either 
homo- or heteropentamers. In that way, up to four different subunits can be combined 
in a single pentameric receptor (1). 
Due to their abundance in the nervous system and their large diversity, pLGICs are 
important therapeutic targets for the treatment of different diseases. Therapeutic 
applications reach from the treatment of schizophrenia, Alzheimer’s and Parkinson’s 
disease to smoking cessation and anesthesia. Very potent toxins that target pLGICs 
were also identified and find their use as insecticides and antiparasidic drugs. 
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Prokaryotic homologues 
Ion homeostasis and electrical signaling through ion channels is important to all 
phylae of life. It is therefore not surprising that related genes, e.g. those coding for 
shaker-type potassium channels and voltage gated sodium channels, were found in 
genomes of multi- and unicellular eukaryotes as well as in genomes of prokaryotes 
(2). In contrast, genes coding for pLGICs were initially only found in the phylum of 
animals. It was therefore believed that only organisms with a nervous system 
possess genes coding for pLGICs. This contradicted a phylogenetic analysis among 
the pLGICs, which stated that the common ancestor of all pLGICs appeared 2.5 
billion years ago (3), long before the appearance of the first eukaryotes. Through the 
advances in genome sequencing, more genomes of prokaryotic organisms became 
available and finally, in 2005, Tasneem et al published the identification of 
prokaryotic pLGICs (4). Even though the sequence conservation is below 20%, the 
key residues of the family are well conserved. In 2006, Bocquet et al showed the first 
heterologous expression of GLIC, the pLGIC of the cyanobacterium Gloebacter 
violaceus. The protein was successfully expressed in E.coli, HEK293 cells and 
Xenopus laevis oocytes. The work has identified GLIC as pH-activated, cation 
selective ion channel and it confirmed the pentameric structure of the protein by 
electron microscopy and unspecific crosslinking (5). 
 
Structural information of pLGICs 
The first view of a component of a pLGIC at high resolution was obtained in 2001, 
when Brejc et al determined the structure of the acetylcholine binding protein of the 
mollusk Lymnaea stagnalis by X-ray crystallography. This protein is homologous to 
the ligand binding domain of the nAChR and it is most probably involved in the 
regulation of nonsynaptic cholinergic signal transmission (6). The structure at 2.7Å 
provided insight in the pentameric organization of the extracellular ligand binding 
domain, the location and architecture of the ligand binding sites and the binding 
modes of ligands. The structure also revealed the effect of neurotoxins like α-
bungarotoxin and α-connotoxin on a molecular level (7). 
Following on a long term effort to determine the structure of a full-length channel by 
electron microscopy, in 2003, Miyazawa et al determined the 4Å EM structure of a 
nAChR in tubular crystals formed from membranes of the electric organ of Torpedo 
marmorata. In 2005, they used crystallographic refinement methods to improve the 
model. Despite the comparably low resolution, they were able to interpret the electron 
density map and build a model containing most of the protein backbone and the side 
chains of bulky aromatic residues. This pioneering work has provided the first 
structural information on a full length pLGIC and it lead to the first hypothesis of the 
gating mechanism (8, 9). 
In 2004, the identification of prokaryotic homologues also nourished the hope to 
determine a high resolution structure of a bacterial family member by X-ray 
crystallography. As it was shown in several cases, prokaryotic homologues have 
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characteristics that make them very superior targets for crystallization when 
compared to eukaryotic proteins. Prokaryotic proteins are usually more compact, they 
do not contain post translational modifications, such as glycosylations and, in case of 
ion channels, their regulation is often tighter than that of their eukaryotic counterparts. 
These features are exploited in the structure determination of membrane proteins. In 
2008 and 2009, the structures of two homologues were determined by X-ray 
crystallography. The structure of ELIC, the homologue of Erwinia chrysanthemi (10), 
was followed the previously described pH activated GLIC (11, 12). ELIC and GLIC 
provided the first insights into the architecture of full receptors at high resolution, as 
they were determined 3.3Å and 3.1Å respectively. Both structures had a large impact 
on the understanding of the architecture of these ion channels and they also 
suggested an initial mechanism of gating which is relevant for the entire family. In 
2011, the first crystal structure of a eukaryotic pLGIC, GluCl of Caenorhabditis 
elegans, was solved at 3.3Å. GluCl was the first structure of an anion selective 
member of the family and provided detailed insight into agonist binding, anion 
selectivity and the allosteric modulation by ivermectin (13). 
 
  
Figure 1 Top and side view of the available structures of pLGICs. The membrane is indicated as grey bars. A 
comparison of the cartoon representations of the secondary structure elements reveals the strong structural 
conservation within the family. Each of the five protomers is formed by an extracellular domain which consists of 
two β-sheets and a transmembrane domain of four α-helices. The residues of the second transmembrane helix 
line the pore which spans the membrane along the symmetry axis of the pentamer. 
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Despite the low similarity on the sequence level, all existing structures underline the 
conservation within the family (Figure 1). As all members of the family, they are 
pentamers. Each subunit consists of a mainly beta stranded extracellular ligand 
binding domain and a transmembrane domain formed by four transmembrane 
helices. The extracellular domains surround a wide and water-filled vestibule giving 
access to the pore, which is formed by the second transmembrane helices of all five 
subunits. 
The extracellular domain 
The pentameric assembly of the extracellular domains is a cylindrical structure with a 
height of 60Å and a diameter of 80Å. The protein domains enclose a large 20Å wide 
aqueous vestibule in the center of the pentamer (Figure 2). Viewed along the five-fold 
axis, it resembles a windmill with petal-like protomers. Each of the protomers consists 
of ten β-strands forming a β-sandwich with an immunoglobulin-like fold. In the 
pentamer, the only contacts of the subunits are dimer interfaces. Every protomer has 
two interaction sites; one on the principal and another on the complementary side. 
This interaction interface is very large with a buried surface of about 2500Å2. The 
agonist binding site is a part of this subunit interface as the ligand binding pocket is 
formed by the β-strands and loops from both the principal and the complementary 
subunits (7). In contrast to the large interface between the protomers of the 
extracellular domain, the interface between the extracellular and the transmembrane 
domain is comparably small. The contacts are mediated by three loops of the 
extracellular domain and the M2-M3 loop of the transmembrane domain. These loops 
are strongly conserved within the family and they are responsible to transmit the 
conformational changes of the extracellular domain upon agonist binding to the pore. 
 
 
Figure 2 The structure of the acetylcholine binding protein of T.californica representing the extracellular domain of 
the AChR with the typical pentameric assembly of the pLGIC family. (left) The side view shows the ligand binding 
site, indicated by the bound carbachol. It is located in the large interface between the principal (blue) and the 
complementary (red) subunit. (right) The top view along the fivefold axis depicts the windmill-like structure of the 
pentamer formed by five subunits. It encloses a large vestibule in the center of the pentamer, which gives access 
to the pore in the full receptor. 
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The pore 
Early studies with chimeric AChRs revealed a link between the conductance and the 
second transmembrane helix, the M2 segment of the receptor (14). Later on, it was 
shown that mutations in the M2 of AChRs altered the ion conduction properties and 
the affinity of a voltage dependent pore blocker. Therefore the M2 helix was 
attributed to be involved in the formation of the pore. In the 90’s, the substituted 
cystein accessibility method (SCAM) was used in AChRs, GABARs and 5HT3R to 
identify water accessible residues in the transmembrane domain (15–17). 
Interestingly, these studies found that every third or fourth amino acid in M2 was 
prone to modification and it was thus concluded that M2 had to be the pore lining 
helix and that the pore itself is formed by the side chains of all five M2 helices, one of 
each subunit of the pentamer. This was later confirmed by structural biology. 
As known from sequence alignments, the chemical properties of the pore lining 
residues are conserved throughout the family of pLGICs. The extracellular halve of 
the pore is formed by three rings of hydrophobic amino acids (labeled as positions 9’, 
13’ and 16’ in the nomenclature derived for the nAChR), followed by two rings of 
polar residues (2’ and 6’). The cytosolic ring (-1’) varies in dependence of the 
selectivity of the channel. It is formed by glutamates in cation-selective and alanines 
in anion selective receptors. 
The location of the gate was subject of controversial discussions. Miazawa et al 
reported in their EM structure from the resting state of the AChR a constriction at the 
hydrophobic 9’ position of the pore. The diameter of the pore in this region is 3Å. 
Even though the pore is not fully obstructed computational simulations suggest that 
this diameter in a hydrophobic environment would form a barrier for sodium ions and 
can therefore act as a gate for the ion channel (18). 
Similar results were obtained from experiments using photoaffinity labeling of the 
AChR with the radiolabeled noncompetitive antagonist 3-(trifluoromethyl)-3-(m-
[125I]iodophenyl)diazirin (TID), which was applied to the extracellular lumen of the 
channel. In the absence of agonist, TID specifically labeled the hydrophobic amino 
acids at the 9’ and 13’ position. In the presence of agonist, TID was able to penetrate 
deeper into the pore and label the polar residues at the 2’ and 6’ position. These 
results are consistent with a gate formed by the hydrophobic rings at the extracellular 
halve of the pore (19). 
After the success of SCAM in identifying the pore lining residues, Wilson and Karlin 
applied this method to achieve a state-specific labeling of the AChR (20). By 
measuring electrophysiologically the time-dependence of the reaction of the 
introduced cysteines with MTS reagents applied from the extra- and intracellular side, 
they calculated the rate constants of the modification. They found that the residues at 
the -1’ and 2’ position at the intracellular part of the pore can be labeled much faster 
if the channel is in the open conformation than in the closed or desensitized state. 
Therefore they concluded that the residues at the -1’ and 2’ position form the 
activation gate. Additionally, they observed that the reaction rates of the introduced 
cysteines at position 6’ and 9’ dropped significantly if the receptor was in the 
desensitized state. In this way they could show that the pore lining is altered in these 
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3 different states of the receptor and they postulated a desensitization gate that 
reaches from the -1’ position to the 9’ position. 
 
 
Figure 3 (top) Sequence alignment of the pore forming M2 helix of GLIC, ELIC and AChR. The pore lining 
residues are conserved and form six rings with distinct chemical properties. The three hydrophobic rings on the 
extracellular side constitute the gate, whereas the inner two polar and the intracellular charged ring build the 
selectivity filter. (bottom) Comparison of the pore structures of ELIC and GLIC showing two conformational states. 
ELIC is in a non-conductive state, in which the hydrophobic rings obstruct the pore. The GLIC pore is in the open 
conformation, where the hydrophobic rings separated from each other to open the gate whereas the polar and 
charged rings contracted to form a selectivity filter. 
 
The structure of ELIC was the first pLGIC resolved at high resolution. It was 
crystallized in the absence of agonists and shows a non-conducting conformation. 
The pore is completely obstructed by two hydrophobic rings formed by the residues 
at the 9’ and 16’ position (Figure 3). The alanines of the third hydrophobic ring at the 
13’ position line a cavity of hydrophobic nature, where xenon atoms were trapped 
(10). Even though it is not entirely clear if this structure represents a resting or a 
desensitized state, it clearly supports the model where the amino acids of position 9’ 
to 16’ form the activation gate as the overall chemical characteristics of the pore of 
the AChR are also conserved in ELIC and GLIC. In contrast to ELIC, the structure of 
GLIC reveals a pLGIC in the active state. The hydrophobic residues of the activation 
gate have separated from each other, whereas the polar and charged rings have 
contracted to form a selectivity filter. This conformational change leads to the 
formation of a funnel-shaped and aqueous pore, which allows ions to pass through 
the membrane. The first high resolution structure of a eukaryotic homologue was 
determined in a conductive conformation which is almost equivalent to GLIC (13). 
The high degree of structural conservation between prokaryotic and eukaryotic 
receptors is very likely to extend to the mechanism of channel gating. It emphasizes 
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the suitability of the prokaryotic homologues as model systems, to gain a deep 
understanding into the molecular mechanisms underlying the function of pLGIC. 
 
Activation of pLGICs 
Since the middle of the last century, pharmacologists are inventing and refining 
mathematical models to describe the quantitative activity of drugs on a receptor, 
called drug receptor theory. These models are derived from enzyme kinetics and 
form the major link between the experimental observations and the events taking 
place on a molecular level. The first dose response experiments on a pLGIC, 
performed on Torpedo electroplax and frog endplates, showed that the obtained 
curves were not related to a classical hyperbolic Langmuir curve. This classical 
model assumes the agonist to interact with identical and independent binding sites 
and simply the occupancy of a receptor with an agonist leads to activation. The 
obtained curves in contrast, were sigmoid and accompanied by a slope bigger than 
one in a Hill plot. Since the receptors showed a cooperative behavior similar to the 
observations in hemoglobin, it was concluded that the receptors contain several 
allosterically linked agonist binding sites. Del Castillo and Katz also found that the 
classical model failed to explain their findings of partial agonism and therefore 
postulated a two state model where an agonist A binds to a receptor R to form an AR 
complex that is still not conducting. This complex can subsequently undergo a 
conformational change to the active state AR* (21). 
 
Figure 4 A schematic representation of the del Castillo-Katz model of receptor activation. The vacant receptor 
binds the agonist to form an agonist-bound but inactive complex. This step only depends on the affinity of the 
agonist to the receptor. In the second step, the receptor undergoes a conformational change which leads to the 
active and conductive state. This transition is dependent on the efficacy E, a measure of the ability of the agonist 
to convert the receptor to its active state. 
The first step in this model requires the binding of the agonist to the receptor and this 
step is only dependent on the affinity of the agonist. The second step is the structural 
reorientation of the receptor and its equilibrium constant is called efficacy. The 
efficacy is an intrinsic property of the agonist, describing its potency to activate the 
channel. Using this model, del Castillo and Katz could finally explain the observation 
that partial agonist could not evoke the same response as full agonists even at full 
occupancy of the receptor, simply by stating that the efficacy of the partial agonist is 
smaller than the efficacy of a full agonist. 
From the theory of cooperative enzymes, Monod et al proposed a model of pLGICs 
as allosteric proteins which could coexist in both open and closed states (22). This 
model is similar to the two state model of Del Castillo and Katz, but it includes an 
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open state without agonist bound to the receptor and a state with two agonists bound 
to the receptor. 
 
Figure 5 The schematic representation of the Monod-Wyman-Changeux (MWC) model of allosteric receptor 
activation. In this model, the receptor can adopt both the inactive and the active conformation in the presence or 
absence of agonist. The agonist can stabilize the active conformation and as a result, the efficacies increase from 
the unliganded to the biliganded state. It also follows that the active conformation has a much higher affinity to the 
agonist than the inactive conformation, which can explain the cooperative behavior in the activation of pLGICs. 
This model predicts that the channel can be active in the absence of the agonist, 
even though this state is not highly populated as the efficacy of the unliganded 
receptor is very low. With higher occupancy of the receptor, also the efficacy of the 
conformational change is increasing.  
The first use of this model was to explain the experimental findings of constitutive 
activity in pLGICs where the model of Del Castillo and Katz failed. For certain 
receptors, very short openings were observed in the absence of agonist and 
mutations were identified that increased the probability of these openings, thus 
confirming the constitutive activity (23, 24). Furthermore, this model also includes 
distinct affinities for the agonist in the closed and the open state, as observed 
previously and it also explains the cooperative behavior of the receptors. With several 
ligand binding sites, the concerted movement of the different subunits from the 
resting to the active state creates cooperativity even without increasing the actual 
affinity of the individual binding sites (25). 
The problem in the measurement of dose-response curves of LGICs is that the 
affinity of the agonist to the receptor and its efficacy are coupled as the response of 
open channels is measured upon application of agonist. The determined constant of 
a dose response experiment is the agonist concentration at the halve-maximal 
response, termed the EC50. It gives the apparent affinity of an agonist to its receptor 
because it is a measurement that unites the two microscopic constants affinity and 
efficacy. The EC50 is related to the affinity and efficacy by the following equation: 
50 = D1 +  
Therefore, neither the true affinity nor the efficacy of an agonist can be determined by 
dose-response experiments and furthermore, if the EC50 is changed by a mutation in 
  
17 
the receptor or by a modulator, it cannot be determined if the affinity or the efficacy 
has changed. 
Ligand recognition in the extracellular domain 
The first step to the activation of a pLGIC is the binding of the ligand to the receptor. 
The best studied receptor in terms of ligand recognition is the AChR. The ligand 
binding site was expected to be part of the extracellular domain as the permanently 
positive charged ammonium group of ACh cannot diffuse through the membrane. 
The first information about the location of the binding site came for specific 
crossinking studies. Silman and Karlin showed that bromo-ACh activated the receptor 
and got covalently linked to a disulfide bond that had to be in vicinity of the ligand 
binding site (26). From the knowledge of the primary sequence, site directed 
mutagenesis and chemical labeling, the residues involved in ligand binding were 
identified. From this information it became obvious that amino acids from six loops 
(A-F) contributed to ligand binding, loop A-C from the principal and loop D-F from the 
complementary subunit (27). The first structures confirmed the hypothesis of a multi-
loop binding site located in the interface of two adjacent subunits called the principal 
and the complementary side. In the structure of AChBP in complex with carbachol 
(28), the ligand binding pocket is mainly formed by a network of aromatic residues 
interacting with the ligand (Figure 6). There are three tyrosines (Y89, Y185, Y192) 
and one tryptophan (W143) from the principal side as well as one tryptophan (W53) 
from the complementary side. They stabilize the positive charge of the quaternary 
ammonium. Other hydrophobic contacts involve the disulfide bond (S187, S188) from 
the principal and a methionine (M114) and a leucine (L112) from the complimentary 
side. Also arginine 104 interacts with carbachol but the interaction is not of ionic 
nature.  
The interactions of different agonists have been studied, also in the context of the 
AChBP. Nicotine is a neurotoxin and a very potent agonist of AChRs. The 
interactions in the binding site are comparable to carbachol as it also shows 
interactions with the aromatic side chains (Figure 7). Additionally, nicotine interacts 
through hydrogen bonds with the backbone carboxyl and amide groups of leucine 10, 
methionine 114 and tryptophan 143. This explains the much higher binding affinity of 
nicotine compared to carbachol. 
As previously described, the main interaction of the cationic agonist carbachol with 
the protein is not mediated by salt bridges but by interactions with the π-electrons of 
the aromatic residues in the pocket, called cation-π interaction. The lab of Dennis 
Dougherty developed a method to quantify the cation-π interaction in pLGICs. They 
use a nonsense suppression method in X.laevis oocytes to introduce artificial amino 
acids in the receptor, in this case fluorinated aromatic amino acids. The fluorine 
withdraws the electrons from the aromatic ring due to its high electronegativity and 
with increasing the degree of fluorination, the capacity for an interaction with a cation 
decreases. The effect of the fluorinated amino acids is measured by determination of 
the EC50 by electrophysiology. 
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Figure 6 The secondary structure of the acetylcholine binding protein (AChBP) depicted as cartoon 
representation. The carbachol indicates the agonist binding pocket located in the dimer interface of the principal 
and complementary subunit. Carbachol is bound in the multi-loop binding site. It is interacting with residues of 
loop A to E. The main interactions in the ligand binding site are the cation-π interaction of the quaternary amine 
moiety with the aromatic ring formed by the tyrosines and tryptophans. 
 
Experiments with an AChR containing a fluorinated tryptophan of loop B (residue 143 
in AChBP numbering) with ACh and carbachol showed a linear dependence of the 
EC50 on the degree of fluorination. The fluorination of the other aromatic residues in 
the ligand binding pocket did not produce a similar shift in the EC50, clearly 
demonstrating that the cation-π interaction is the main source of the interaction of 
tryptophan 143 with the natural agonists (29). Nicotine on the other hand exhibited a 
different behavior. In the same experiment, the EC50 of nicotine was independent of 
the fluorination of the tryptophan (30). These experiments proved that the 
physiological agonists ACh and carbachol exhibit a different binding mode than the 
neurotoxin nicotine, even though all of them are able to activate the receptor (Figure 
7). 
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Figure 7 Detailed representation of the interactions of carbachol and nicotine in the ligand binding pocket of the 
AChBP. The binding mode of carbachol is mainly determined by the cation-π interaction, stabilizing the positive 
charge. The other amino acids interact with the agonist via van der Waal’s contacts. Even the positively charged 
arginine 104 does not form an ionic interaction with carbachol. Nicotine is interacting differently. No cation-π 
interaction is required as the secondary and tertiary amino moieties are stabilized by hydrogen bonds to the 
protein backbone. Due to these interactions, nicotine has a much higher affinity to the AChR than carbachol. 
 
The same method was also applied to 5HT3, GABA and glycine receptors whose 
aromatic amino acids in the ligand binding sites were fluorinated. The effects on the 
EC50s are homologous to the AChR. Like the AChR, the 5HT3 receptor contains a 
tryptophan in the loop B, responsible for the cation-π interaction. In GABA and 
glycine receptors, there are two amino acids involved in a cation-π interaction with 
the agonist. They are tyrosines in the case of GABA receptors and phenylalanines in 
the case of glycine receptors. Equivalent to the ACh and 5HT3 receptors, one of them 
is located on loop B. The other position is unique to GABA and glycine receptors and 
located on loop C (31, 32). All pLGICs thus share a similar chemistry for ligand 
binding and, despite this interaction was first observed in AChRs, it is even stronger 
in GABA and Gly receptors. 
The chemistry involved in ligand recognition and binding is strongly conserved within 
the family of pLGICs. Despite there is no single determinant for agonist specificity, 
the activation of different receptors is very specific to their agonists. The agonist 
specificity is achieved through the interplay of all the residues which interact with the 
agonist, as they are distributed over all the loops within the ligand binding pocket 
(33). 
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Conformational changes 
Movements of the ligand binding site upon ligand binding 
The ligand binding domain is a dynamic structure that exists in different 
conformational states. pLGICs have a low affinity to their ligands in the closed, 
resting state and a higher affinity in the active open, state, reflecting the 
conformational changes in the ligand binding domain which ultimately lead to the 
activation of the channel. Upon prolonged exposure to the agonist, pLGICs enter a 
desensitized, closed state with an up to a thousand-fold higher affinity for the ligand 
than the active state. According to the ligand binding affinities, at least three different 
conformations of the ligand-binding domain are proposed to exist. 
The conformational changes upon ligand binding were investigated using the AChBP 
from Alpysia californica. The protein was crystallized in the apo form and in complex 
with several agonists and antagonists (34). The most prominent difference in the 
structures was identified in loop C. Upon agonist binding, the loop undergoes an 
inward rigid body movement of 7Å. This movement, called loop C capping, closes the 
ligand binding pocket. In the presence of the antagonist α-conotoxin, the loop swings 
outward by about 4Å (Figure 8). Apart from the movements of loop C, there was also 
a minor outward movement of loop F observed in certain subunits. 
The restriction of the ligand-induced conformational changes in the AChBP to the 
capping movement of loop C raised the question if the AChBPs are good model 
systems to understand channel activation. Although they are very homologous to the 
ligand binding domains of the AChR, the loops that interact with the transmembrane 
domain in the full receptor are different. No conformational change was detected in 
these loops so that the mechanism of signal transmission from the ligand binding site 
to the gate of the channel still remained to be elucidated. Additionally, agonist binding 
to pLGICs is highly cooperative, whereas the binding to the AChBP is not. Still, 
several observations in full length receptors are in accordance with the structural data 
obtained from AChBPs. Differences in the accessibility of residues in the AChR 
probed by  deuterium exchange experiments, showed that residues of the loop C are 
less accessible in the presence of agonist, which is consistent with C loop capping 
(35). Additionally, Bouzat et al produced a functional chimera of the AChBP and the 
transmembrane domain of a 5HT3 receptor by adopting the loops that interact with 
the pore (36). This indicates that C loop capping might trigger a conformational 
change leading to activation. Even though the AChBPs cannot explain all aspects of 
the gating mechanism, similar movements of the loop C have been observed in the 
full receptors and seem to be conserved in the family. 
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Figure 8 Mechanism of C-loop capping derived from structures of the AChBP, crystallized in the apo-, agonist- 
and antagonist bound state. The C-loop experiences a contraction from the apo structure (in green) to the agonist 
bound structure (in blue). This conformational change is believed to be the first step in the activation process of 
pLGICs. Antagonists on the other hand were found to push the C-loop outwards, corresponding to the observed 
difference between the apo structure (in green) and the antagonist bound structure (in red). Competitive inhibitors 
are therefore believed to inhibit receptor activation by preventing the C-loop capping. 
 
Further insights into the conformational changes underlying channel activation were 
gained with the structures of the prokaryotic homologues ELIC and GLIC. GLIC is a 
proton gated channel and the region of the consensus ligand-binding site is filled with 
protonable side-chains of residues of the respective loops A-F. Ligand recognition in 
GLIC is therefore believed to occur by alteration of the protonation state of these 
amino acids although the residues involved in proton sensing still have to be 
elucidated. Despite the differences of the activation ligand, both pLGICs allowed first 
insights into potential structural changes of full length receptors upon ligand binding 
as GLIC was crystallized at low pH in a conductive conformation whereas the 
structure of ELIC was solved in the absence of agonist showing a non-conductive 
state.  
The comparison of the two structures reveals large conformational differences in the 
extracellular domains. Very striking again is the loop C capping in GLIC compared to 
ELIC. Rearrangements are also evident for the F loop as well as the β1-β2 and the 
cys-loop, the main regions interacting with the transmembrane domain. The best way 
to describe the conformational change between GLIC and ELIC is a 12° rotation 
around an axis parallel to the two beta sheets of the extracellular domain (Figure 9) 
(37). It will have to be shown whether this relation is truly representative for a 
movement of the extracellular domain upon agonist binding. 
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Figure 9 Conformational differences between the structures of ELIC and GLIC. Both the movements of the 
extracellular and the transmembrane domain can be described as rotations. The extracellular domain is rotated 
along an axis between the β-sheets. The movements in the transmembrane are restricted to the helices M2 and 
M3. They rotate along an axis parallel to the membrane. This movement was hypothesized to open the gate of 
the channel during the activation process. 
 
Gating 
LGICs are allosteric proteins. Binding of the ligand to its binding site in the 
extracellular domain triggers a conformational change in the molecule, which is 
transmitted over several nanometers to the pore. 
The structures of both prokaryotic homologues offered insight into potential structural 
transitions of the pore upon gating. In contrast to the ELIC, the pore of GLIC is open, 
showing a funnel shaped and water accessible cavity that allows ion to flow through 
the membrane. The most striking difference between the two structures is found in 
the conformation of the transmembrane helices M2 and M3. As encountered before, 
the pore of ELIC is completely obstructed whereas in GLIC, the M2 and M3 helices 
underwent a 12° rotation relative to ELIC. This movement separates the three 
hydrophobic rings at the 9’ to 16’ positions, opening the gate of the ion channel. In 
contrast to the extracellular halve of the pore, the two polar and the charged rings at 
positions -1’ to 6’ moved closer, thereby forming a polar constriction that only allows 
desolvated ions to pass (37). 
There are several interaction sites that potentially transmit the conformational 
changes in the extracellular domain upon ligand-binding to the transmembrane 
domain. The interface couples the independent movements of the two domains. The 
main interaction site in the pore region is the M2/M3 loop, which closely interacts with 
the cys-loop and the β1/β2 loop of the ligand binding domain. The involved regions 
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are highly conserved throughout the family. The comparison of the structures of ELIC 
and GLIC shows only minor changes in the cys-loop, whereas the β1/β2 loop adopts 
different conformations (Figure 10). In GLIC, the lysine at the tip of the loop interacts 
tightly with a proline on the M2/M3 loop, keeping the pore in the open conformation. 
This interaction is not evident in the structure of ELIC, where the equivalent residues 
are about 7Å apart. A salt-bridge that was identified in GLIC to stabilize the 
interaction between the β1/β2 loop and the pre M1 region, is absent in ELIC, which 
might be the cause of the big movement of the β1/β2 loop. 
 
Figure 10 Differences between the ELIC and the GLIC structures in the coupling interface of the extracellular and 
the transmembrane domain. The interaction of the residue at the tip of the β1/β2 loop with the M2/M3 loop is 
believed to couple the movement of the domains. The schematic representation depicts the interactions in the 
principal pathway of coupling, where the signal of agonist binding is transmitted to the M2/M3 loop via the β1/β2 
loop which is additionally stabilized by a hydrogen bond to the pre M1 region. 
 
The laboratory of Steven Sine used single channel recording and thermodynamic 
mutant cycle analysis to investigate the interactions involved in gating of the AChR. 
They identified interactions of the β1/β2 loop and the cys loop with the M2M3 loop as 
well as the salt-bridge of the β1/β2 loop to the pre M1 as the main elements for 
coupling. The interactions were thus termed the principal pathway of coupling (38–
40). 
 
Desensitization 
Desensitization is the reversible decrease or loss of a biological response upon 
prolonged or repetitive stimulation. Upon exposure to high concentrations of their 
agonist, pLGIC adapt an open conformation which exists only transiently. If the 
agonist is applied for a prolonged time, the channel closes by entering a desensitized 
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state. This is visible in electrophysiological experiments as a steady decline of 
macroscopic current in the presence of agonist. pLGICs desensitize also if they were 
purified and reconstituted, therefore desensitization has to be an intrinsic property of 
the receptors and it is not mediated by cytosolic components of the cells (41). The 
recovery from desensitization is a slow process that can only take place if the agonist 
is completely removed because desensitization can occur at very low concentrations 
of the agonist. The mechanism of desensitization can only be explained by a circular 
model where the receptors exist is at least 3 different states, the resting (R), active 
(R*) and desensitized state (D). In contrast to the transition from the R to the R* 
state, that requires high agonist concentrations, the transition from the R to the D 
state can already be induced by much lower concentrations. Consequently the D 
state must have an at least twentyfold higher affinity to the agonist (42). An 
intermediate desensitized state (I) was introduced to account for the observations 
that the decrease of the current due to desensitization shows a biexponential 
behavior and the time the receptor needs to recover from desensitization is 
dependant of the duration of the prior agonist exposure. For the muscle AChR the 
affinities of the different states were determined. The dissociation constant of the 
resting state is 50-100µM, of the intermediate state is 1µM and the desensitized state 
is 1nM. 
Desensitization represents a classical property of allosteric proteins. The receptor 
population is distributed among different states of discrete conformations. Also in the 
absence of agonist, a small proportion populates the D state. The most recent 
quantifications report a fraction below 1% of the receptors (43). Due to the high 
affinity of the D state to the agonist, the receptors can be quantitatively desensitized 
by low concentrations of agonist without activating the receptor. On the other hand, 
the estimated rate of dissociation of the agonist from the desensitized state is much 
faster than the rate of recovery and it is therefore assumed that the recovery from 
desensitization is independent of the agonist affinity (44). 
Even though desensitization is an intrinsic feature of almost all pLGICs, the 
physiological function is still ambiguous. In synapses, neurotransmitters are instantly 
reabsorbed or degraded and only present for several milliseconds but the 
desensitization rates of most pLGICs are on the second time scale and thus much 
slower. Desensitization could still accumulate during repetitive excitations of a 
synapse. The most common explanations are that desensitization is either a 
mechanism for the protection of the cells against excitotoxicity (41) or a mechanism 
to shape the short term plasticity of synapses. 
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Ion selectivity and conductance in pLGICs 
Ions are hydrated in aqueous solutions and the energy difference of a naked Na+ ion 
placed in a lipid bilayer compared to its hydrated state was estimated to be 164kJmol-
1. This high energy difference makes ions virtually insoluble in the low dielectric 
environment of the lipid bilayer, which therefore forms a potent barrier for ions. The 
water filled pores of ion channels offer a low energy path for ion through the 
membrane. The main determinants of selective ion permeation of an ion channel are 
the pore radius and the electrostatic interactions between the channel pore and the 
transported ion. It is obvious that a small pore radius can prevent bigger ions from 
passing through the pore, but also the chemical properties of the pore lining residues 
have to be taken into account for ion permeation. Calculations showed that a pore 
consisting of hydrophobic amino acids, despite being filled with water, would create 
an image potential of the entering ion. This image potential has the same charge as 
the ion and is strongest at the narrowest constriction of the pore. This leads to a 
strong repulsion which makes ion transport unfavorable, at least at physiological 
membrane potentials (45). The introduction of hydrophilic or charged amino acids 
into the pore reduces this energetic barrier and allows ion flux through the channel. 
The combination of the steric features and the polar and charged residues make an 
ion channel capable to discriminate between different ions. 
The selectivity filter of an ion channel is usually located at the narrowest position in 
the pore. It consists of polar or charged groups that coordinate the ion during their 
passage it through the pore. One of the best understood ion channel is the potassium 
channel KcsA, since its structure revealed basis of its selectivity. The selectivity filter 
is formed by backbone carbonyl groups of all four chains of the tetramer. The main 
chain atoms are oriented in a way that the oxygen atoms of the carbonyl groups can 
exactly replace the water of the hydration shell of potassium. The interactions of the 
carbonyls with potassium compensate for the energetic costs of the removal of their 
hydration shell. In contrast, the desolvation energy of a sodium ion is much larger 
and it is too small to be coordinated with similar efficiency. Anions are simply 
electrostatically repelled by the selectivity filter. The potassium channel selectivity 
filter is an elongated structure with a diameter of about 3Å which contains multiple ion 
binding sites. It can accommodate two potassium ions in an almost fully dehydrated 
state at the same time which is important for the mechanism of permeation (46). 
Compared to potassium channels, pLGICs are not as selective. The cation selective 
receptors do not discriminate between monovalent cations and additionally, they 
conduct divalent and even bigger organic cations. Also anion selective receptors do 
not discriminate between different halide anions and they conduct big anions such as 
nitrate, thiocyanate and formate. Due to this poor selectivity, pLGIC are termed 
charge selective. 
The open pore of pLGICs is a funnel shaped structure with a constriction that is 
located at the intracellular, hydrophilic mouth of the channel. The diameter of the 
selectivity filter was estimated to be about 5-9Å, depending on the experimental 
technique and the receptor (15, 16, 47). The high resolution structures of the pLGICs 
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GLIC and GluCl show conducting conformations of the pore. Their structures 
revealed a constriction of 5-6Å in both cation- and anion-selective channels (13, 48). 
Due to their larger pore radius and the fact that they are only charge selective, the 
selectivity filter of pLGIC is thought to conduct ions that are only partially dehydrated. 
The main determinants of charge selectivity in pLGICs consist of the pore lining 
amino acids at the intracellular mouth of the channel. Site directed mutagenesis 
studies in the AChR revealed that the removal of this negative charge altered the 
permeability ratio of magnesium ions relative to potassium and decreased the 
conductance of potassium (49). Based on sequence conservation of the M2 helix of 
AChRs and GlyR, mutations were introduced to alter the charge selectivity of the 
receptors. Interestingly, only three mutations were necessary to reverse the 
selectivity of AChRs. The valine at position 13’ was replaced with a threonine, the 
negatively charged residue at -1’ was removed by truncation to alanine and a proline 
was inserted at the -2’ position (50). Equivalent mutations could also change 5HT3Rs 
from cation to anion selective (51). 
Similar mutations converting the charge selectivity of GlyRs allowed to identify the 
selectivity filter at the constricted region of the pore. The GlyR lost most of its anion 
selectivity when either the alanine at the -1’ position was mutated to glutamate or the 
proline of the -2’ position was deleted. If the two mutations were combined, the GlyR 
was cation selective (52). The equivalent mutations in GABAR also resulted in cation 
selective channels (53). 
The structures of GLIC and GluCl confirm these earlier findings and reveal the 
structural basis for ion selectivity in pLGICs. Electrostatic calculations show that the 
entire pore of GLIC is negatively charged with the strongest charge at the intracellular 
mouth of the channel. GluCl carries a weak negative charge at the extracellular side 
of the pore, whereas the selectivity filer is strongly positively charged (Figure 11). The 
intracellular constrictions in both structures were shown to bind ions, caesium and 
rubidium in GLIC and iodide in GluCl, thus revealing a specific interaction of the ions 
with the selectivity filter. These structures thus suggest that the main determinants of 
ion selectivity in pLGICs comes from the electrostatic potential of the pore which 
attracts ions of opposite charge and repels ions carrying the same charge as the pore 
(11, 13). It is remarkable that cation selective pLGICs require negatively charged 
amino acid side chains in the pore region, whereas anion selective channels do not 
contain charged groups lining the transmembrane part of the pore. This feature may 
be due to the fact that anion selective channels exploit the positive dipole moment at 
the N-terminus of the M2-helix to create the positive charge required for their 
selectivity. Cation selective channels, in contrast, would have to insert a negative 
charge at the end of the helix, the -1’ position, to introduce the negative charge 
required for cation selectivity. 
Two positions at the extra- and intracellular mouth of the pore were identified to be 
essential for the permeability of divalent cations. If the negative ring at the position -1’ 
in the AChR is mutated, the channel is still permeable to monovalent but no longer to 
divalent cations (50). A GlyR, carrying the three mutations converting its selectivity 
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from anion- to cation selective, was found to be weakly permeable to divalent cations. 
The receptor harbors a positively charged ring of arginines at the 19’ position at the 
extracellular entrance of the pore. The removal of this ring increased the permeability 
of divalent cations, even more if a ring of negative charges was introduced (52). 
These results underline the importance of negative charges at the intracellular and 
extracellular mouth of the pore for cation selectivity and the permeation of divalent 
cations. 
 
Figure 11 The calculated surface potential of the cation selective GLIC and the anion selective GluCl are shown 
(negative potential red and positive potential blue). The figure highlights the role of the electrostatic potential on 
the underlying mechanism of the charge selectivity of pLGICs. They create an attractive environment for the 
conducted ions and an insurmountable barrier for their counterions. 
 
Determinants of conductance 
The chemistry of the pore lining residues does not only alter the ion selectivity but 
also the conduction properties pLGICs. Several positions along the ion permeation 
pathway alter the conductance of the channel. The removal of the negative ring at 
the -1’ position at the intracellular mouth of the AChR reduced the single channel 
conductance from 80 to 20 pS (49). Polar substitutions at the 2’ position increased 
the conductance, whereas the introduction of non-polar amino acids decreased the 
conductance inversely proportional to their size (54). 
Charged rings at the extracellular entrance of the pore also affected the conductance 
in AChRs, GlyRs and GABARs. The mutant inverting the charge selectivity of the 
GlyR contains a ring of arginines at the 19’ position, which is unusual for native cation 
selective pLGICs. The substitution by alanine increased the conductance from 7pS to 
14pS. The effect is even stronger if a negative charged glutamate is introduced at 
this position, increasing the conductivity to 22pS (50). 
Next to the pore itself, also the intracellular domain located between M3 and M4 can 
influence the ion conduction. Three arginines matching the pattern of an α-helix were 
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identified on the intracellular domain a 5HT3R subtype and the mutation of all of them 
in a homopentameric receptor increased the conductance from <1pS to 20pS (55). 
Finally, also the wide extracellular vestibule contributes to the conductance of the 
channel. Using the structure of the AChBP, Hansen et al identified a conserved site 
in the vestibule of the extracellular domain of pLGICs. All cation selective receptors 
carry an aspartate at this position, whereas it is a lysine in anion selective receptors. 
By charge reversal mutations of this position in the AChR, they showed that the 
single channel conductance decreased fivefold (56). This charged ring in the 
vestibule of pLGICs is thought to initially stabilize the conducted ions and thereby 
increasing their local concentration. A similar feature is also observed in the 
comparison of the electrostatic potential of the extracellular vestibule of GLIC and 
GluCl (Figure 11). GLIC is cation selective and its vestibule is negatively charged 
whereas it is positively charged in the anion selective GluCl. 
The positions influencing the permeation of ions across pLGICs are thus not 
concentrated in a single location of the protein. Similar to the determinants of ion 
selectivity, the charged surface of the entire ion permeation pathway, including the 
pore and the extracellular vestibule, determines the conductance of the receptors. 
 
Modulation of pLGICs 
Thanks to their important function in the central nervous system, pLGICs are targets 
of a variety of drugs as well as natural and artificial toxins. All of these compounds 
work by modulating the function of the target receptor, either by enhancing or 
inhibiting the response to the agonist which is called positive or negative modulation. 
Modulators are divided in three groups depending of their site and mechanism of 
action. The first group is formed by pore blockers, the second by orthosteric ligands 
which bind to the agonist binding site whereas the third group contains allosteric 
modulators which act at a site remote from the agonist binding site. 
Pore Block 
The simplest case of inhibition is pore block, where the ion flux is obstructed by the 
binding of the blocker and thereby the total response to agonist is reduced. Pore 
block is a general mechanism of inhibition of ion channels and it is pharmaceutically 
exploited, e.g. in the block of voltage gated sodium channels by the local anesthetic 
lidocaine (57). Big cations like tetraalkylammonium ions, quinacrine or lidocaine were 
also identified as inhibitors of the AChR and GLIC (58–61). A recent functional and 
structural investigation of GLIC showed that these molecules indeed bind to a site in 
the open pore. As shown by X-ray crystallography, the charged moiety of lidocaine is 
located close to the polar residue at the 6’ position whereas its bulky aromatic part is 
localized close to the 9’ and 13’ positions. The study thus confirmed that open pore 
blockers act by physically obstructing the pore as there are too big to permeate 
though the channel and thereby prevent other ions to enter the pore and pass 
through the channel (62). 
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Competitive Inhibition 
Competitive inhibitors are orthosteric ligands that bind to the agonist binding site but, 
in contrast to an agonist, they fail to trigger the conformational changes that open the 
channel and instead even stabilize the resting conformation of the receptor. The 
agonist can compete with the antagonist for the binding site and thereby remove the 
inhibitor from the binding site. The inhibition by a competitive antagonist is therefore 
surmountable as all receptors can still be activated if the agonist concentration is high 
enough. In the presence of a competitive inhibitor, a dose response curve of a 
receptor shifts to higher agonist concentrations. This shift will not saturate because a 
higher concentration of inhibitor can always be surmounted by an even higher 
concentration of agonist. Competitive inhibitors are known for all members of the 
pLGIC family. There are small molecules, such as plant alkaloids which act as potent 
competitive antagonists. The most famous antagonists are DHβE and d-tubocurarine, 
both acting on AChRs, strychnine acting on GlyRs, bicuculline on GABARs and 
morphine and methadone on the 5HT3Rs. Besides these small inhibitors, a variety of 
animals, such as snails or snakes, evolved specific peptide toxins, like Bungarotoxin 
or α-conotoxin, acting as competitive antagonists of AChRs. 
The affinity of a competitive inhibitor can be analyzed using the displacement of the 
agonist dose response curves by a Schild plot which was derived from the Gaddum 
equation (63, 64): 
log − 1 = log − 2 
Where DR is the dose ratio, meaning the ratio of equiactive agonist concentrations in 
the absence and presence of inhibitor (e.g.

 ), [B] is the concentration of the 
inhibitor and pA2 corresponds to the logarithm of the dissociation constant KB of the 
inhibitor. A plot of [B] against (DR-1) in a double logarithmic graph gives a linear 
relationship with a slope of unity and the intercept pA2 which is the logarithm of the 
inhibitor concentration that is required to double the equiactive concentration of the 
agonist. This value corresponds to the dissociation constant of the inhibitor. 
 
Figure 12 (a) Dose response curves of a receptor activated by its agonist at different concentrations of a 
competitive inhibitor. Due to the presence of the inhibitor, the curves shift to higher agonist concentrations. The 
data is transformed to the dose ratio at the corresponding antagonist concentrations and plotted in a Schild plot 
(b). The dissociation constant of the inhibitor can be deduced from the x-axis intercept. 
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Partial agonists 
Another class of orthosteric modulators is formed by partial agonists. Partial agonists 
are often chemically related to the full agonist of a receptor. They bind to the same 
site as the agonist but only produce a small maximum response even at 
concentrations where the receptor is fully occupied. For 50 years partial agonism was 
explained by a difference in the efficacy of gating. The equilibrium of the gating step 
for a full agonist lies at the open state, whereas for a partial agonist it is shifted 
towards the closed state (21). The most thorough study on partial agonism was 
performed on the AchR and the GlyR (65). Based on the analysis of single channel 
events at different concentrations of full or partial agonists, a new intermediate state 
(flipped) was proposed. The flipped state was interpreted to correspond to a 
conformational rearrangement in the extracellular domain upon ligand binding prior to 
channel opening, for example the wrapping of the C loop around the ligand as 
proposed for C loop capping. It was also shown that the difference between full and 
partial agonist is not the equilibrium of the gating step, but rather of the transition 
between the resting ligand bound state and the flipped state. 
 
Allosteric modulators 
As previously described, pLGICs are allosteric proteins that exist in several 
conformations or states. The various conformations are occupied according to the 
differences in free energy by a Boltzman distribution. The receptors thus form a 
dynamic system of changing conformations. An allosteric modulator may have a high 
affinity for one or several of these states and bind to these once they are formed. 
Thereby the relative free energy of the states changes and the native equilibrium of 
conformations are biased towards the conformations bound by the allosteric 
modulator. This stabilization of a conformation can lead to multiple structural changes 
compared to the native protein and modify several properties of the receptor. Due to 
the coupling between different parts of the molecule, the binding site of the modulator 
can be remote from the site that is functionally affected by the modulation and there 
is no need for a direct interaction as the modulation is transmitted through the 
protein. 
Allosteric modulators can act in two different ways on pLGICs. They can change the 
affinity of the receptor to the agonist by influence the equilibrium of the transition 
between the closed and the open state once the ligand is bound to the receptor. 
Depending on the compound, these effects can be positive or negative. Positive 
modulators are therefore also called allosteric potentiators, whereas negative 
modulators are termed allosteric inhibitors.  
As previously seen, a change of either the affinity or efficacy shifts the EC50 and it 
requires further investigations to determine if the allosteric modulator is influencing 
the affinity of the agonist, the efficacy of gating or both of it. Regardless of the origin 
of the displacement of the dose response curves in the presence of antagonist, this 
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shift can be used to determine the pA2-value and thereby the affinity of the modulator 
in a similar way as in the case of competitive inhibition. 
One difference to competitive antagonism is that the effect of allosteric modulator is 
saturable. Therefore, the Schild equation is modified for allosteric modulators using a 
cooperativity factor α (64). 
log − 1 = log1 −  − log  + 2 
A negative modulator has α<1 which will cause a shift of the dose response curve to 
higher agonist concentrations, whereas a positive modulator has α>1, resulting in a 
shift to lower concentrations of agonist. This also means that at theoretically infinite 
concentration of the modulator, the apparent affinity to the agonist will saturate at 
D
 . 
For allosteric inhibitors, the magnitude of α is inversely proportional to the ability to 
act like a competitive inhibitor. The adapted Schild equation for allosteric modulators 
becomes the Schild equation of competitive inhibitors if α is very small. Therefore in 
the case of allosteric inhibitors, if α is small and the tested inhibitor concentration 
range cannot reach saturation, it is possible to use the standard Schild plot for the 
determination of the affinity of the inhibitor without introducing a large error. 
 
Figure 13 Effects of different allosteric modulators on the agonist dose response curves at increasing modulator 
concentrations. (a) Negative allosteric modulators shift the dose response curve to higher agonist concentrations 
whereas positive allosteric modulators cause a shift to lower agonist concentrations. The saturation of the effect is 
a hallmark of allosteric modulation. In the case of insurmountable allosteric inhibition (c), also the maximum 
response decreases next to the shift of the dose response curves. (d) Schild plot of allosteric inhibitors depicting 
the influence of the cooperativity factor α. If α is small, the saturation of inhibition is only apparent at very high 
concentrations of the antagonist and the inhibition appears to be competitive. 
 
The modified Schild equation above was developed for surmountable allosteric 
modulators that reduce the affinity of the receptor to the agonist. If the allosteric 
modulator is not affecting the affinity to the agonist but the efficacy of the receptor 
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itself, a reduction of the maximum response occurs next to the displacement of the 
dose response curve. The Schild method can also be used in this case to measure 
the potency of such an insurmountable allosteric antagonist, but the pA2-value of the 
Schild regression is then related to the true KB by following expression: 
B = pA2− log #1 + 2D $ 
In the case of an allosteric inhibitor in combination with a highly efficacious agonist, 
the ratio 
%
D is small and together with the low cooperativity factor α, the impact of the 
insurmountable property is diminished. Therefore, the pA2-value of the Schild 
regression is a very good estimate for the true dissociation constant of an allosteric 
insurmountable inhibitor. 
Several allosteric modulators of pLGICs have been discovered and characterized. All 
of them have distinct binding sites in the in the receptor, distant from the agonist 
binding site. 
Benzodiazepines are widely used therapeutic compounds that potentiate GABARs. 
Benzodiazepines bind to a site in the extracellular domain located in the interface of 
the γ- and α-subunit, topologically equivalent to the ligand binding site. 
Benzodiazepines cannot activate the channel on their own but they allosterically 
increase the apparent affinity of the receptor to its agonist GABA which is binding to 
its binding site in the β- and α-subunit interface (66). 
Also alcohols and general anesthetics are known to modulate different pLGICs and 
their effects depend on receptor type and subunit composition. Ethanol has been 
shown to potentiate AChRs and 5HT3Rs whereas longer alcohols have an inhibiting 
effect. In contrast, all alcohols have a potentiating effect on GlyRs and GABARs. 
Similar to long chain alcohols, general anesthetics are inhibitors of AChRs but 
potentiate GABARs and GlyRs (67). The binding site of both alcohols and general 
anesthetics is located in the transmembrane domain. For the AChR and 5HT3R, 
residues of the M2 helix were identified to be critical for the potentiation by ethanol 
(68) and anesthethics (69). Recently it was found that GLIC is also inhibited by the 
general anesthetics Propofol and Desflurane. In contrast to previous studies, both 
anesthetics were found to bind from the lipid bilayer to a cavity located between M1 
and M4. Desflurane was found deeply buried in the cavity and to hydrophobically 
interact with all four transmembrane helices. Propofol on the other hand was found 
sandwiched between M1 and M4, not interacting with M2 and M3 (70). 
Ivermectin is a macrocyclic lactone from the family of the avermecins that are 
produced by certain bacteria. Ivermectin is an allosteric potentiator of GluCl, the 
glutamate activated pLGIC of invertebrates. GABARs and GlyRs are also affected by 
ivermectin but they are about thousand fold less sensitive than GluCls. Mutational 
studies of the ligand binding site of GluCl could decrease the response to glutamate 
but failed to affect the response to ivermectin and therefore showed that the binding 
sites of glutamate and ivermectin do not overlap (71).Certain isoforms of GlyRs and 
GABARs can even be activated by ivermectin only (72, 73).  
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The question about the binding site and the mechanism of potentiation was finally 
resolved with the structure of a GluCl from C.elegans. It was shown that ivermectin 
binds in the transmembrane domain between the M3 of the principal and the M1 of 
the complimentary subunit. It inserts deeply into the subunit interface where it forms a 
hydrogen bond with a serine on M2 and it interacts closely with the M2M3 loop. By 
comparing the structure of GluCl to GLIC and ELIC, it was hypothesized that 
ivermectin is activating GluCl by separating M1 and M3 by 3Å and thereby pulling top 
of the M2 away from the center of the pore. This movement is thought to open the 
gate by adopting a conductive conformation with a pore structure very similar to GLIC 
(13). 
Next to these big organic compounds, small inorganic cations such as calcium, 
magnesium and zinc are known to modulate the function of pLGICs. The effect is 
dependent of the receptors type, as AChRs are potentiated by calcium ions whereas 
5HT3Rs are inhibited (74–76). AchRs and 5HT3R are also potentiated by zinc ions 
where GlyRs and GABARs are inhibited (77–79). These studies have postulated 
different binding sites for the interaction with divalent cations, either located in the 
pore of the channel or the extracellular domain in the interface between the subunits. 
The calcium interaction site for the potentiation of AChRs was found to consist of a 
glutamate in the loop F as the potentiation was lost upon a mutation to glutamine (50, 
80). The inhibition of 5HT3Rs by calcium was found to be associated to the ligand 
binding site and to appear as competitive inhibition (81). The equivalent sites in loop 
F as identified in the AChR were also mutated in the 5HT3 receptor but the mutants 
still showed modulation by divalent cations. A mutation of an aspartate at the 
extracellular mouth of the pore to alanine was found to abolish the modulation by 
calcium. Therefore it was concluded that the interaction site for divalent cations in the 
5HT3Rs is located in the pore (82, 83). Mutational analysis of GABARs revealed that 
the binding site of zinc is located in the extracellular domain between the subunits 
and is formed by histidines and glutamates. Interestingly, this site is located at a 
similar position as proposed for the AchRs (79). 
Although it is believed that the regulation of pLGICs by divalent cations plays an 
important role in the physiology of these receptors, and despite the fact that the effect 
has been described in different studies, the underlying mechanism is still poorly 
understood. 
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Aim of the work 
The function of pLGICs is well understood and very detailed models of receptor 
function were developed, but the formulation of a molecular mechanism was 
impossible for a long time due to a lack of high resolution structures. The first 
mechanisms were proposed using the 4Å EM-structure of the AChR and the crystal 
structures of the AChBPs. These mechanisms based on the information collected 
from many different sources, because it was still not possible to obtain high resolution 
structural and the corresponding functional data from the same native receptor. This 
only changed with the high resolution structures of the two prokaryotic homologues 
ELIC and GLIC and the eukaryotic GluCl. 
The structure of ELIC has offered the first insights at high resolution into the 
architecture of pLGICs. In combination with the two structures of GLIC and GluCl, 
ELIC has contributed to the comprehension of selective ion conduction, but our 
mechanistic understanding of the gating process is still poorly understood. Both GLIC 
and GluCl suffer from certain drawbacks if used as model systems. The activation of 
GLIC is not dependent on the binding of small molecular agonist but on the 
protonation state of the receptor itself, a ligand recognition mechanism not found in 
eukaryotic pLGICs. The structure of GluCl was solved from a truncated 
homopentamer of the α-subunit, which is only partially activatable by its native 
agonist glutamate and requires the allosteric modulator ivermectin for full activation. 
The use of GluCl for functional studies might thus be limited. Therefore, ELIC 
remained an attractive model system for pLGICs where detailed structural and 
functional studies could be carried out on the same protein. Moreover, its 
compactness and the possibility to produce milligram amounts of protein, makes 
ELIC accessible for spectroscopic studies and calorimetry. Unfortunately, nothing 
was known about the function of ELIC at the beginning of this thesis. 
The first aim of this thesis was to identify molecules that act as agonists on ELIC and 
to characterize the functional properties of ELIC with respect to channel opening, 
agonist binding and ion permeation. Next to establishing ELIC as a model system for 
the pLGIC family, a second goal was to stabilize the open state of the protein to 
make it accessible for the structure determination of ELIC in a conducting 
conformation. The first question was successfully addressed with results described in 
the first publication about the ligand activation of ELIC. The second question proved 
to be challenging and has so far not yet been successfully approached. 
The second aim of this thesis was raised during the work with ELIC. It was realized 
that divalent cations are very potent in reducing the current elicited by ELIC. Divalent 
cations are known to be important modulators of pLGICs. Due to the high functional 
similarity of ELIC to eukaryotic receptors, the goal of this second project was to 
identify the origin of this inhibition and to elucidate its mechanism using both 
structural and functional assays. The study has revealed insight into the mechanism 
of inhibition by divalent cations and is described in the second publication. 
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Results 
Ligand Activation of the Prokaryotic Pentameric 
Ligand-Gated Ion Channel ELIC 
ELIC was initially identified as a prokaryotic member of the pLGIC family based on 
sequence conservation. Its structure, which was recently determined at high 
resolution, is highly conserved compared to eukaryotic receptors, and thus confirmed 
the close relationship between pro- and eukaryotic channels. In contrast to our 
structural knowledge, little is known about the physiological role of ELIC in bacteria. 
Thus it was difficult to deduce which molecules could trigger ELIC activation. This 
major drawback had to be overcome before ELIC becomes accessible to detailed 
structure-function investigations. 
The first publication in this thesis summarizes the results on the identification of ELIC 
agonists and the initial biophysical characterization of the channel. Different 
expression systems in combination with various electrophysiological methods were 
investigated for their suitability for agonist screening. Transiently transfected HEK 
293 cells showed robust surface expression of ELIC and could be used to measure 
ELIC mediated currents in a planar patch clamp setup. Also the reconstitution of 
purified ELIC in liposomes and their fusion to an artificial bilayer was tested. Both 
systems turned out to be inappropriate for agonist screening, as the application of 
different compounds led to a loss of the patch or resulted in rupture of the bilayer. 
Therefore, a more robust system, the expression of ELIC in X.laevis oocytes was 
combined with two-electrode voltage-clamp for agonist screening. 
A library of compounds was assembled based on the available structural information 
on the ligand binding pocket (Figure 14). The structural alignment revealed that the 
binding pockets of AChBP and ELIC are of similar size, even though sequence 
alignments showed a stronger conservation of ELIC to the GABARs and GlyRs. 
Further, it was known from earlier structural investigations that inorganic monovalent 
cations bind to the ligand binding pocket, thus implying that the agonist should be 
cationic as well (10). The library thus contained about 250 organic cations of similar 
size as known neurotransmitters. 
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Figure 14 (left) The superposition of the ligand binding sites of AChBP (gray) and ELIC (principal side green, 
complementary side orange) reveals a pocket that is similar in size and conserved in its chemical character. 
(right) The ligand binding site of ELIC binds inorganic monovalent cations. The red and blue mesh shows the 
anomalous difference densities of the coordinated Tl+ and Cs+ ions respectively. The conservation of the ligand 
binding residues is indicated by the corresponding amino acids of selected eukaryotic pLGICs. The strong 
conservation to GABARs and GlyRs is evident. 
 
Several molecules of this library were found to evoke currents in ELIC expressing 
oocytes. The potency of these molecules was quantified by the measurement of dose 
response relationships. Both the apparent affinities and the maximal evoked currents 
of all agonists were determined and compared to cysteamine, the most potent of the 
identified ligands. X-ray crystallography was used to identify the agonist binding site 
of ELIC. In addition, the biophysical properties of ELIC, its ion selectivity and single 
channel conductance as well as activation and deactivation kinetics were determined 
by patch clamp electrophysiology and recording of reconstituted protein in artificial 
bilayers. 
The results place ELIC in the branch of the cation-selective pLGICs. As all the 
functional properties of ELIC are similar to the eukaryotic receptors, the results from 
investigations performed on ELIC are representative for pLGICs. 
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Inhibition of the Prokaryotic Ligand-Gated Ion 
Channel ELIC by Divalent Cations 
Almost all eukaryotic pLGICs are modulated by different divalent cations, either in a 
positive or a negative manner. Even though the physiological context of this 
modulation is not entirely understood, it is believed to play an important role in 
regulating the synaptic response. During an initial biophysical characterization of 
ELIC, it was realized that calcium ions inhibit the ion permeation. In experiments, 
where agonist and divalent cations are co-applied to the activated receptor, a 
decrease of the current is observed (Figure 15). Dose response relationships can be 
used to determine the potency of the inhibitor. However, all inhibitors behave similar 
in such experiments, irrespective of their mechanism of action and it is thus 
impossible to distinguish between pore blockers, competitive or allosteric inhibitors. 
To clarify the mechanism of the modulation of ELIC by divalent cations, different 
electrophysiological experiments were combined with X-ray crystallography. 
 
 
Figure 15 2EVC traces of a X.laevis oocyte expressing ELIC clamped at -40mV. In each experiment, ELIC is 
activated by 5mM cysteamine (cya) followed by the co-application of different inhibitors. These are the 
competitive inhibitor ACh, the pore blocker TBA and the divalent cation Ca2+. The difference in current before and 
after the application of the inhibitors is due to the desensitization of ELIC. In this experiment, the phenotype of the 
inhibition is indistinguishable between the different kinds of inhibitors.  
 
A detailed investigation by electrophysiology revealed a complex behavior of ELIC in 
the presence of divalent cations. With increasing calcium concentrations, the dose 
response curve shifts to higher agonist concentrations. This effect was not found to 
saturate, even at high concentrations. Additionally, it was noticed that the maximal 
evoked current is not affected at low concentrations of divalent cations, where the 
inhibition is surmountable. At higher concentrations, however, the maximal current is 
decreased and the inhibition is no longer surmountable. The different effects could be 
interpreted by two distinct mechanisms, acting at low and high concentrations of 
divalent cations. This behavior resembles the effect of calcium on 5HT3 receptors 
and it suggests that divalent cations act by a conserved mechanism of inhibition 
which can be deduced in ELIC by a combination of structural and functional 
investigations. 
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In our study, we found that divalent cations act as negative allosteric modulators of 
ELIC by decreasing the efficacy of channel gating. Even though three different 
binding sites for divalent cations were identified by X-ray crystallography, only one of 
them is functionally important and accounts for all the facets the complex pattern of 
inhibition. Interestingly, the divalent cation binding sites of several eukaryotic 
receptors were mapped to positions similar to the identified site in ELIC. It implies 
that the same location in the receptors is responsible for either positive or negative 
allosteric modulation. 
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Supplementary Table 
 
Table S1 Dose-response relationships of agonists in the presence of different 
modulators 
  [mM] EC50
* n   [mM] EC50
* n 
WT Ca2+ 0 0.36 2.8 WT Ca2+ 0.1 0.35 2.9 
WT Ca2+ 0.25 0.64 3.2 WT Ca2+ 0.5 1.00 2.9 
WT Ca2+ 1.0 1.73 2.9 WT Ca2+ 2.5 2.46 3.0 
WT Ca2+ 5.0 4.37 2.5      
WT/BAPTA Ca2+ 0 0.36 2.7 WT/BAPTA Ca2+ 0.25 0.84 2.1 
WT/BAPTA Ca2+ 0.5 1.07 2.4 WT/BAPTA Ca2+ 1.0 2.23 2.3 
WT ACh 1 0.57 2.5 WT ACh 5.0 1.49 2.4 
WT ACh 10.0 2.25 2.5      
WT/0.25Ca2+ ACh 0 0.64 3.2 WT/0.25Ca2+ ACh 1 1.16 1.9 
WT/0.25Ca2+ ACh 5 3.46 2.4 WT/0.25Ca2+ ACh 10 5.08 2.1 
WT/0.5Ca2+ ACh 0 1.00 3.7 WT/0.5Ca2+ ACh 1 1.83 2.5 
WT/0.5Ca2+ ACh 5 4.03 2.2 WT/0.5Ca2+ ACh 10 8.45 2.7 
WT/1Ca2+ ACh 0 1.73 2.8 WT/1Ca2+ ACh 1 2.68 2.0 
WT/1Ca2+ ACh 5 5.12 2.4 WT/1Ca2+ ACh 10 8.24 1.9 
WT Zn2+ 0.01 0.92 3.2 WT Zn2+ 0.05 3.72 2.2 
WT Zn2+ 0.1 10.1 2.3      
WT Ba2+ 1 0.76 3.7 WT Ba2+ 5 2.68 2.3 
WT Ba2+ 10 5.27 2.3      
WT Sr2+ 1 0.75 2.9 WT Sr2+ 5 2.11 2.7 
WT Sr2+ 10 3.41 2.3      
WT Mg2+ 1 1.04 3.1 WT Mg2+ 5 3.05 2.4 
WT Mg2+ 10 5.31 2.1      
D86A Ca2+ 0 0.57 2.3 D86A Ca2+ 1 2.30 2.1 
D86A Ca2+ 5 5.31 1.9 D86A Ca2+ 10 11.2 2.9 
S84A Ca2+ 0 0.36 2.5 S84A Ca2+ 1 1.55 1.6 
S84A Ca2+ 5 2.74 1.9 S84A Ca2+ 10 5.43 1.4 
N251A Ca2+ 0 0.29 2.3 N251A Ca2+ 1 0.84 3.5 
N251A Ca2+ 5 1.90 2.7 S84A Ca2+ 10 5.31 1.8 
E150A Ca2+ 0 1.40 2.4 E150A Ca2+ 1 2.20 2.6 
E150A Ca2+ 5 6.10 2.0 E150A Ca2+ 10 8.99 1.9 
E150Q Ca2+ 0 2.92 2.8 E150Q Ca2+ 1 5.29 2.0 
E150Q Ca2+ 5 14.6 1.9 E150Q Ca2+ 10 21.9 1.8 
D113A  Ca2+ 0 0.95 2.6 D113A Ca2+ 1 0.88 2.2 
D113A  Ca2+ 2.5 1.46 1.8 D113A Ca2+ 5 1.86 1.9 
D113A  Ca2+ 10 2.90 1.9 D113A Ca2+ 25 6.37 1.5 
D113N Ca2+ 0 0.92 2.5 D113N Ca2+ 1 1.81 2.1 
D113N Ca2+ 5 5.59 1.8 D113N Ca2+ 10 9.78 1.9 
D158A  Ca2+ 0 1.78 2.6 D158A Ca2+ 1 1.79 3.2 
D158A  Ca2+ 5 3.33 3.1 D158A Ca2+ 10 5.43 2.0 
D158A  Ca2+ 20 9.38 2.0      
D158N Ca2+ 0 3.88 2.5 D158N Ca2+ 1 5.61 2.1 
D158N Ca2+ 5 8.50 1.9 D158N Ca2+ 10 11.2 2.0 
113A/158A Ca2+ 0 2.33 2.6 113A/158A Ca2+ 1 1.59 3.5 
113A/158A Ca2+ 5 1.81 2.9 113A/158A Ca2+ 10 2.96 2.6 
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113A/158A Ca2+ 25 3.35 2.4      
113A/158A Zn2+ 0 3.70 1.4 113A/158A Zn2+ 0.01 4.56 2.0 
113A/158A Zn2+ 0.1 4.22 1.7      
  [mM] Ec50 n   [mM] Ec50 n 
113A/158A Ba2+ 1 3.07 2.3 113A/158A Ba2+ 5 3.07 2.1 
113A/158A Ba2+ 10 5.42 2.2      
R91A Ca2+ 0 0.09 2.6 R91A Ca2+ 0.5 0.24 1.7 
R91A Ca2+ 1 0.41 1.8 R91A Ca2+ 5 0.92 1.7 
R91A ACh 1 0.40 3.2 R91A ACh 5 0.88 3.3 
R91A ACh 10 1.78 2.7      
R91A TMA 10 0.23 2.4 R91A TMA 25 0.33 2.4 
R91A TMA 50 0.59 2.5      
H168A Zn2+ 0 0.67 3.0 H168A Zn2+ 0.01 1.17 2.5 
H168A Zn2+ 0.05 4.82 2.1 H168A Zn2+ 0.1 12.2 1.9 
H176A Zn2+ 0 5.16 2.3 H176A Zn2+ 0.01 11.9 2.5 
H176A Zn2+ 0.025 25.5 1.9      
 
Propylamine was used as agonist in experiments involving Zn2+, cysteamine in all 
other cases. 
*EC50 in mM 
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Supplementary Discussion 
The experimental data we have to explain 
By binding to Sout, extracellular calcium produces several, apparently disparate 
effects on functional ELIC responses.  These effects are additional to the reduction in 
single channel conductance and independent of it.   
These modulatory effects of calcium include: 
1) a reduction in the potency of agonists, which results in a parallel shift to the right of 
the agonist dose-response curve.  This effect appears at low calcium concentration 
(0.1-1 mM) and is not associated with changes in the agonist maximum response.  
2) at higher calcium concentrations (2-5 mM), there is further reduction in agonist 
potency, and this is associated with a pronounced decrease in the agonist maximum 
response (about 50% at 6 mM –channel block subtracted). 
3) low calcium does not affect how fast ELIC channel open when they are saturated 
by agonist, but increases the concentration of agonist needed to reach this “limiting” 
rate of opening.  
4) the decreases in agonist potency produced by calcium and those produced by the 
competitive antagonist acetylcholine are independent, namely they are unaffected by 
the presence or absence of the other.  
 
The effects of calcium on the agonist dose-response relation can be explained by a 
decrease in efficacy within a simple del Castillo-Katz activation mechanism  
The simplest scheme for the activation of a ligand-gated ion channel was proposed 
by Jose’ del Castillo and Bernard Katz in 1957[1].  In this scheme  
(1) 
activation involves two steps. The first is the binding of the agonist A to the channel 
R, with microscopic affinity described by the dissociation constant Kd (itself the ratio 
between the dissociation rate constant koff and the association rate constant kon).  
The second step is a conformational change, where the agonist-bound resting 
receptor (AR) opens to the conducting form AR*.  The position of the equilibrium 
between AR and AR* is described by an equilibrium constant E, that reflects agonist 
efficacy and is the ratio between the opening rate constant β and the closing rate 
constant α.  
More complex schemes are needed to explain all the aspects of channel functional 
behaviour, and such schemes incorporate the existence of more than one agonist 
binding site, the possibility of unliganded and partially-liganded openings, 
intermediate states in the conformational change and desensitisation.  Nevertheless, 
the del Castillo-Katz scheme is sufficient to describe much of basic channel 
pharmacology (reviewed in ref. [2] and exploring it gives useful insight.   
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Indeed, if we look only at the ELIC equilibrium responses (ie the agonist dose-
response curves), all the effects of calcium can be explained within the del Castillo-
Katz mechanism, just by assuming 1) that calcium decreases agonist efficacy E and 
2) that full agonist efficacy E is high in ELIC. 
The value of efficacy E  
The second assumption appears to be quite plausible. In the del Castillo-Katz 
mechanism, the channel open probability is given by  
&'() = ∗%%∗+,+- (2) 
Maximum open probability (Popen) is  
./0	&'() = +,  (3) 
and the EC50 for the agonist is  
50 = -+,   (4) 
Figure 1A shows that cysteamine opens ELIC channels with a high maximum open 
probability.  Our single channel data (Marabelli et al., in preparation) suggest that the 
maximum Popen reaches 98%.  From Equation 3, this implies that agonist efficacy is 
of the order of 50 (50/51= 98%).  This value is not dissimilar to that seen for other 
members of the superfamily, such as the nicotinic ACh receptor and the glycine 
receptor, when they are activated by full agonists. 
The effects of decreasing efficacy  
When efficacy E is this high, the effects of a small decrease in E on the maximum 
agonist response are hard to detect in practice.  For instance, a two-fold decrease in 
E would reduce maximum open probability from 98% to 96% (that is from 50/51 to 
25/26).   
Even a two-fold decrease in E would however cause a detectable shift in agonist 
potency, as the agonist EC50 would almost double (see equation 4).  This is in line 
with the observations at low calcium concentrations. 
It is only when the decrease in E is much larger, and E drops to values below 10, that 
a decline in the maximum Popen becomes noticeable, as the maximum Popen falls 
below 90%.  This is in line with our observations at higher calcium concentrations, 
where more of the calcium binding sites are occupied and calcium can have a greater 
effect on E.   
Thus there is no need to hypothesize that low calcium and high calcium have 
different microscopic effects: a progressive decrease in agonist efficacy E, more 
marked at the higher calcium concentrations, is all that is needed to explain our 
observations. 
A more detailed activation mechanism is required to explain the lack of an effect of 
calcium on the limiting rate of channel gating  
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In another set of experiments we produced ELIC currents by near-instantaneous 
applications of agonists (“concentration jumps”) to channels in outside-out patches.  
The time course with which these currents reach their steady-state value depends in 
principle on all the rate constants in the activation mechanism.  However, if agonist is 
applied at concentrations that are very high and saturate the receptor, it can be 
shown that these maximum agonist current responses effectively increase as single 
exponentials with time constant  
2 = ,3+	   (5) 
where β is the opening rate constant and α the closing rate constant [3,4].  
We already know that efficacy E is high for ELIC. As efficacy is the ratio of β /α, the 
value of β must be much bigger than that of α (50-fold), and therefore the time 
constant is influenced mostly by the value of β .   
If calcium decreases E (as we have to assume, in order to explain its effects on the 
agonist dose-response curves), it can do so either by decreasing β or by increasing 
α. Neither of these effects can be reconciled with our observations, if the del Castillo-
Katz scheme is valid for our channel, because we did not observe a change in the 
limiting rate of gating or in the time course of the current at the end of the agonist 
pulse (deactivation). From the arguments above, it is clear that if there is a decrease 
in β, we should see a slowing of the maximum rate of current development and that 
this should be detectable even for fairly small changes in β. If, on the other hand 
calcium decreases E by increasing α, the limiting rate of gating would not change 
(given that β >>α), but speeding the channel closing rate α should result in a faster 
decline in the current when the agonist pulse ends, that is a speeding up of 
deactivation, which was not observed either.   
Thus it may be that the del Castillo-Katz model is inadequate to explain the action of 
calcium. Indeed, it could be that activation of the channel requires not a single 
conformational change, but two. If the rate-limiting step for gating in the agonist jump 
experiments is not opening, but an earlier, slower step, calcium could still change 
efficacy and shift agonist potency and maximum responses without affecting the time 
course of the current in our agonist concentration jumps.   
This is because, if reaching this reaction intermediate is slow enough, the agonist 
limiting relaxation will be dominated by this step, rather than by the opening itself. 
This explanation is qualitatively plausible because mechanisms incorporating 
reaction intermediates are necessary to explain the single channel kinetic properties 
of channels related to ELIC, such as nicotinic ACh receptors and glycine receptors, 
as shown by our own work and that of the groups of Sine and Auerbach (see main 
discussion, [5-7].  
The simulation below is a proof of principle to show that this explanation is not only 
qualitatively plausible but also that it can work quantitatively, with at least one set of 
rate constant values.   The solution is certainly not unique, and eq.6 is not proposed 
as a complete mechanism for the ELIC receptor. Nevertheless the rate constant 
values used are not unrealistic, as they are not far from our estimates from 
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mechanism fitting of ELIC single channel data (Marabelli et al., in preparation) or 
from rate constants estimated from other pLGICs. 
The simplest mechanism incorporating a reaction intermediate is  
 (6) 
In this minimal “flip” mechanism, there is an additional state AF (for flipped), which is 
still closed but has changed conformation.  The maximum Popen becomes 
./0	&'() = 44+4+,  (7) 
For the calculation of the time course of the saturating agonist responses, the 
mechanism can be simplified by pooling the states separated by a binding step (R 
and AR) into a single state [R,AR].  This can be done because we have a very high 
concentration of agonist A, making the association rate, kon [A] very fast. For the 
same reason, the pooled state [R,AR] is almost entirely made of AR. 
The mechanism then becomes  
  (8) 
 and has four rate constants: β  (open),α (close), f (flip) and b (unflip) and the ratios of 
these give the equilibrium constants E = β /α and F = f/b.  The values of the rate 
constants are constrained because the maximum Popen of the channel is high, 
suggesting that β >>α  and f >=b. 
We know also that the risetime of the current produced by the high concentration 
agonist jump has a time constant of 17-20 ms (this is considerably slower in ELIC 
than in other pLGICs). 
The black trace in Figure SD1A shows the current on-relaxation calculated for this 
mechanism. This is identical to a single exponential with a time constant of 20 ms 
(shown for reference as a red dashed curve). The values used in the calculation were 
β = 50000 s-1, α = 1000 s-1, f = b= 50 s-1.  They make E= 50 and F = 1 and imply a 
maximum Popen of 96%.   
Let’s now assume that we are in the presence of calcium and that calcium has 
reduced efficacy (by decreasing β ) by 5-fold. This would result, as discussed above, 
in a shift in the agonist potency and in a reduction in the maximum Popen (from 96% to 
83%; in the model discussed in the next section, where calcium binding is explicit, 
this would be reached at approximately 1 mM calcium). However, as shown in Figure 
1B, even this fairly strong effect of calcium has only a tiny effect on the risetime of the 
limiting agonist current (the calculated agonist current is shown in black and 
compared to a reference exponential curve with a time constant of 20 ms, red dashed 
curve). Note that for the purpose of showing some effect of calcium in the calculation, 
we have chosen to show the consequences of a reduction in efficacy greater than 
that likely to prevail in our concentration jump experiments (where we had no effect of 
calcium on the maximum response).    
More detailed mechanisms and the equilibrium effects of calcium  
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The arguments above show that incorporating an intermediate state that limits the 
fastest rate of ELIC gating allows us to account for our observations in the agonist 
jump experiments. This more detailed mechanism can still explain the effects of 
calcium on the agonist dose-response curves, and in this section we will show that 
with an appropriate example.   
If we incorporate in the flip mechanism the binding of calcium, we obtain  
  (9) 
 
For clarity, the scheme above shows the names of the equilibrium constants for each 
step (rather than the rate constants as in schemes 1, 6 and 8). Note that KA and KCa 
are the microscopic dissociation constants for the agonist A and for calcium, 
respectively. Calcium is assumed to affect only efficacy, which is reduced from E to 
ECa in the calcium-bound channel (bottom line of the mechanism). 
 
 
Figure SD1 Calcium can reduce efficacy and the maximum open probability of ELIC without changing the 
maximum rate of current onset, if this is limited by the channel’s slow access to an activation 
intermediate.  The black curves in the graphs are the calculated time course of currents produced by 
instantaneous applications of saturating agonist concentrations (at time 0, current expressed as open probability). 
The dashed red curves are single exponentials with time constant of 20 ms and the same maximum values as the 
currents and are shown for reference. Currents are calculated from mechanism (8). The values used in the control 
calculation (0 calcium, graph A) were β = 50000 s-1, α = 1000 s-1, f = b= 50 s-1 . Hence E= 50 and F = 1 (where 
efficacy E is the equilibrium constant for the final opening step and F is the equilibrium constant for access to the 
preceding intermediate state) and the maximum Popen is 96%. (B) Calcium can reduce the value of β by as much 
as 5-fold with negligible effects on the time course of current onset. Note that the steady-state value of this 
maximum current has decreased to a Popen value of 83%. The calculations with the more complete models in 
Figure 2 indicate that this reduction in maximum Popen is expected to occur at approximately 1 mM calcium, e.g. a 
concentration much greater than the one tested in the agonist jump experiments (0.2 mM). 
 
Figure SD2A shows the effect of progressively greater calcium concentrations on the 
dose-response curves for a full agonist.  These effects are calculated from the 
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scheme above, assuming that calcium reduces efficacy by up to 50-fold (when the 
channel is fully bound to calcium) and that E = 50 and F = 1.  The latter values are 
chosen because the maximum Popen is high in control conditions.  
It is clear from the Figure that the lowest calcium concentration (in this example half 
the calcium dissociation constant) shifts the agonist dose-response curve to the right, 
without changing the maximum much. Greater calcium concentrations (at least 5-fold 
the calcium dissociation constant) are required before the maximum response starts 
to decline. We can also plot the agonist dose-response curves after normalising them 
to their maximum response. This shows clearly the parallel shift to the right produced 
by calcium (Figure SD2B).  
 
Figure SD2 The decrease in efficacy induced by calcium results in a reduction in agonist potency at low 
calcium and in an additional decrease in maximum response at high calcium. The graphs show agonist 
concentration-response curves calculated from mechanism (9). This is a mechanism that incorporates an 
intermediate state in the activation of the channel.  The calculations are based on values of E=50 and F=1.  
Calcium is assumed to bind to the resting state of the channel with a microscopic affinity of 0.25 mM (in line with 
the estimate from the Schild plot) and to reduce the value of efficacy by 50-fold when bound to the channel.  The 
agonist concentration is expressed as a multiple of the (unknown) agonist microscopic dissociation constant (KA 
in mechanism 9). In Figure SD2A responses are expressed as absolute Popen values, and in Figure SD2B as 
values normalised to the maximum agonist response. 
 
Plotting the effect of calcium as a Schild plot 
Schild analysis is used in pharmacology to characterise competitive antagonists, 
compounds whose binding is mutually exclusive with that of agonists.  The dose 
ratios (e.g. the shifts) produced by the antagonist in the agonist dose-response 
curves are plotted in a Schild plot, as log(dose ratio-1) against the concentration of 
antagonist (on a log scale).  If the antagonist is competitive, this produces a line with 
a slope of 1.  The intercept between the line and the x-axis estimates the antagonist 
microscopic dissociation constant, a result that is at the basis of receptor 
characterization in classical pharmacology [8]. This result holds also for mechanisms 
that are more complicated than that for which the Schild analysis was originally 
derived [9] 
It may appear surprising that we should see a Schild-like pattern for the effects of 
calcium, given our hypothesis that calcium acts by impairing gating. However, this 
behaviour is predicted if we calculate the Schild plot for the effects of calcium from 
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model (9), with the same assumptions as for the graphs above (namely that calcium 
reduces efficacy by up to 50-fold when the channel is fully bound to calcium and that 
E=50 and F=1).  This is shown in Figure SD3, where the data calculated from the 
model are shown by the black curve and are compared with a reference line (dashed 
red) that has unity slope and intercept equal to the calcium microscopic dissociation 
constant (set to be 0.25 mM in our model, corresponding to -0.6 on the log scale). 
It can be seen that the data follow a Schild-like pattern, particularly at low calcium 
concentration. Remarkably, the Schild plot intercept for the data is a close 
approximation of the true calcium dissociation constant. 
 
Figure SD3 – The concentration dependence of the effects of calcium is close to a Schild-like pattern, 
even though calcium does not act as a competitive antagonist.  The graph shows (black curve) the effect of 
calcium calculated from mechanism (9) and plotted as a Schild plot (see text).  The dashed red line shown for 
reference is what a true Schild relation should look like. This is a line with unity slope that crosses the y=0 axis 
(dashed black horizontal line) at an intercept equal to the calcium affinity (0.25 mM e.g. -0.6 on the log scale). 
Mechanism (9) incorporates an intermediate state in the activation of the channel and assumes E=50 and F=1.  It 
is also assumes that calcium binds to the resting channel with a microscopic affinity of 0.25 mM and that it 
reduces the value of efficacy E by 50-fold when bound to the channel.  Note that the data calculated with these 
assumptions are reasonably close to the true Schild line, particularly at low calcium, where the intercept with the 
y=0 axis is close to the true calcium microscopic binding affinity. 
 
The effects of calcium and those of the competitive antagonist ACh are independent 
We can extend model (9) to include binding of the competitive antagonist ACh.   
In scheme (10), the antagonist B is modelled to bind to the resting state and to bind 
in a manner mutually exclusive with the binding of the agonist A, with a dissociation 
constant KB 
       (10) 
 
We can then calculate the dose-response curves for the agonist either in the 
presence of increasing concentrations of calcium (alone or in the presence of 
saturating ACh, e.g. 20-fold the ACh dissociation constant) or in the presence of 
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increasing concentrations of ACh (alone or in the presence of saturating calcium, e.g. 
20-fold the calcium dissociation constant).  The other assumptions are the same as 
for mechanism (9) (namely that calcium reduces efficacy by up to 50-fold when the 
channel is fully bound to calcium, E=50 and F=1). It has been shown more generally 
[9] that in this sort of mechanism, the effects of blocker B should obey the Schild 
equation if the microscopic affinity of B is not changed by the other ligand (here 
calcium). 
The graphs below (Figure SD4) show that the effects of calcium and ACh are 
independent of each other. This is shown by the fact that calcium produces exactly 
the same reductions in agonist potency, seen as rightward shifts in the normalised 
agonist dose-response curves, whether or not high ACh concentrations are present 
(Figure SD4A and SD4B, respectively). The same applies to ACh (shown alone in 
Figure SD4C and in the presence of high calcium in Figure SD4D).  
 
 
Figure SD4 – The effects of calcium and those of the competitive antagonist ACh are independent.  The 
graphs show agonist concentration-response curves calculated from mechanism (10).  This is a mechanism that 
incorporates an intermediate state in the activation of the channel and assumes that the antagonist ACh can bind 
only to the resting state of the channel, and that ACh binding and agonist binding are mutually exclusive.  The 
calculations are based on values of E=50 and F=1.  In the model, calcium is assumed to bind to the resting state 
of the channel with a microscopic affinity of 0.25 mM (in line with the estimate from the Schild plot) and to reduce 
the value of efficacy by 50-fold when bound to the channel.  ACh is assumed to bind to the resting state of the 
channel with a microscopic affinity of 1.6 mM (from our experimental estimate). The agonist concentration is 
expressed as a multiple of the (unknown) agonist microscopic dissociation constant (KA in mechanism 10). A and 
B show the parallel rightward shifts in the agonist concentration-open probability curves (normalised to the 
maximum open probability) produced by increasing concentrations of calcium (0, 0.25,1.25 and 2.5 mM) when 
calcium is applied alone (A) or in the presence of a saturating concentration of ACh (32 mM, e.g. 20 times the 
ACh dissociation constant, B).  Note that the effect of calcium is the same in A and B. C and D show the parallel 
rightward shifts in the agonist concentration-open probability curves (normalised to the maximum open 
probability) produced by increasing concentrations of ACh (0, 1.6, 3.2 and 8 mM) when ACh is applied alone (A) 
or in the presence of a saturating concentration of calcium (5 mM, e.g. 20 times the calcium dissociation constant, 
B). Note that the effect of ACh is the same in C and D. 
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Discussion 
While the functional behavior of pLGICs has been subject of extensive investigations, 
it is still a difficult task to deduce molecular mechanisms that relate the function of the 
receptors to the available structures, mostly because the necessary structural and 
functional data were not obtained from the same proteins. While the structure of ELIC 
provided the first insight at high resolution into the family of pLGICs, little was known 
about its function and physiology. Without the knowledge of ligands which activate 
ELIC, its use to study the mechanisms underlying the function of the family was 
limited. 
In this thesis I have described the first investigations on structure-function 
relationships in ELIC by using an approach that combines X-ray crystallography and 
electrophysiology. Initially, ELIC agonists were identified by screening a library of 
small molecules. The knowledge of activating ligands has subsequently allowed me 
to study agonist binding and gating in ELIC. The biophysical properties of the open 
pore were characterized by determining the ion selectivity and single channel 
conductance. During the investigations, it was found that divalent cations have an 
inhibiting effect on ELIC, a property which is also known from eukaryotic receptors. In 
subsequent studies I was able to determine the binding site, which is responsible for 
the effect, and to reveal a mechanism for the inhibition of ELIC by divalent cations. 
 
Activation of ELIC 
Agonist Binding 
The first attempts to identify agonists of ELIC during my PhD studies involved an in 
silico docking approach to find molecules which may bind to the canonical agonist 
binding site. These studies were carried out in collaboration with Dr. Peter Kolb and 
are not described in this thesis. Although the selected molecules were subsequently 
tested by electrophysiology, none of them was capable to activate ELIC. In 
retrospect, this is not surprising as the docking was performed with the structure of 
ELIC in the inactive state, whereas the activation likely alters to shape of the binding 
pocket. As the ELIC structure probably shows a resting state, the docking has 
provided a set of molecules which are predicted to bind with high affinity to this state. 
The identified binders thus may act as inhibitors of this allosteric receptor, because in 
contrast to inhibitors, agonists are known to bind the resting state with low affinity, but 
the active state with high affinity. It will be worthwhile to investigate whether any of 
the compounds identified by the docking would act as potent competitive inhibitor. 
In parallel to the computational docking, a library of compounds was assembled 
based on simple structural considerations. These molecules were selected according 
to the chemical environment and the size of the putative agonist binding pocket, 
which was assumed to be at the same location as the canonical binding site of the 
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family. Additional information came from earlier crystallographic studies on ELIC, 
showing the binding of monovalent cations in the ligand binding site (10), which 
indicated that agonists are probably also positively charged. 
The screening of this library on ELIC expressing X.laevis oocytes resulted in the 
identification of eleven molecules capable to activate ELIC. All identified agonists are 
linear primary amines of variable length, containing different functional groups. They 
activate ELIC with apparent affinities in the range from 260µM of cysteamine to 
2.5mM of GABA. The potencies of the identified agonists are low compared to 
eukaryotic receptors, where they range from 0.2-170µM for the AChRs (84, 85), 0.2-
1.5µM for the 5HT3Rs (86), 0.3-30µM for GABARs (87) and 20-50µM for GlyRs (88, 
89). In eukaryotic receptors, the potencies of agonists are also strongly depending on 
the subunit composition of the ion channel. As the apparent affinity is a measure of 
both affinity and efficacy of the agonist, the high variation among the receptors may 
reflect the adaptation of the protein to its tissue specific function (90). If a similar 
adaptation can also be implied for ELIC, the native agonist has to be available in high 
concentrations. The low apparent affinity could additionally help to tightly regulate the 
activity of the channel, to avoid any background activity and related cytotoxic effects. 
With the availability of activating ligands I hoped to be able to stabilize the open 
conformation of ELIC and to determine its structure by X-ray crystallography. 
However, the structures of ELIC in complex with agonists did not show any 
noticeable changes compared to the known structure. As the structure of ELIC in 
complex with the agonist bromopropylamine was only obtained at 4Å resolution, it did 
not allow the detailed characterization of the binding mode of the ligand and its 
interaction with the residues of the agonist binding pocket. The location of the ligand 
was consequently modeled based on the position of the bromine of the bound 
agonist, which was located in the anomalous difference map. The location of the 
ligand binding site of ELIC at the interface between the subunits is equivalent to the 
agonist binding sites of the eukaryotic receptors. As the site shows the strongest 
conservation to the GlyRs and GABARs, it is not surprising that the identified ligands 
are also similar to known agonists of these receptors and it is particularly remarkable 
to find the neurotransmitter GABA is among them. In contrast, substituted amines like 
AChR agonists and bulky primary amines like 5HT3R agonists are ineffective in 
activating ELIC. 
The postulated binding mode of the agonist is in good agreement with the known 
structures of AChBPs and GluCl in complex with their agonists and also supports the 
theory of a common activation mechanism. Interestingly, the highest degree of 
conservation in the ligand binding pocket is found in the residues of the principal 
subunit that interact with the amino moiety of the ligand. Mutations of these amino 
acids result in inactive receptors, thus underlining their significant role in agonist 
binding. In contrast, most of the residues on the complementary side, which are not 
involved in the interaction with the amino group of the agonist, are only marginally 
conserved. Still, these residues play an important role in ligand binding, as the 
mutation R91A increased the apparent affinity for cysteamine and mutations of other 
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residues shifted the EC50 to higher agonist concentrations. Since the mutations in the 
complementary subunit have a less severe effect on activation compared to the 
mutations at the principal subunit, the latter may contribute most to agonist binding by 
stabilizing the positively charged amino moiety of the ligand. The less conserved 
amino acids on the complementary side might be involved in the discrimination of 
different but chemically related agonists. As the determinants of agonist specificity 
are located on several loops of the agonist binding site, receptor activation relies on 
the interplay of all amino acids at this crucial interface between the subunits to 
activate the receptor. 
Gating 
The identification of agonists also allowed an initial analysis of the kinetic properties 
of ELIC. Patch clamp measurements with fast solution exchange revealed a maximal 
macroscopic activation time constant at saturating agonist concentration of 10ms and 
a deactivation time constant of 50ms. The values show that the transitions between 
different states are slower in ELIC than in most eukaryotic receptors, where the 
activation time constants are in the range of 1ms to 4ms for most receptors (91–94). 
The fastest member of the family, the muscle AChR, even activates in the sub-
millisecond time scale. Also the deactivation is slightly faster in eukaryotic receptors 
with time constants ranging from 10-30ms. The kinetic properties of eukaryotic 
receptors are probably adapted to their function in the nervous system to allow fast 
signaling at synapses. For functional investigations, the slower kinetics of ELIC may 
be an advantage, as it allows the investigation of kinetic processes that are too fast 
for concentration jump experiments in many eukaryotic receptors. It may thus be 
possible to detect subtle differences in activation caused by drugs or mutations. 
As most eukaryotic receptors, ELIC enters a desensitized state after prolonged 
exposure to agonist. The discovery of desensitization in ELIC was surprising because 
the previous work on GLIC, another a prokaryotic member of the family, did not show 
any desensitization over an extended time range. As ELIC and GLIC are closer 
related to each other than to the eukaryotic members, ELIC was expected to show 
properties similar to GLIC. Whereas both channels were expected to exhibit a simpler 
functional behavior than eukaryotic counterparts, ELIC was found to share all the 
major functional features of eukaryotic receptors. The initial analysis of single 
channel experiments showed that the open probability during a cluster of channel 
openings is very high, which suggests that the agonists cysteamine and propylamine 
are very efficacious. Two conclusions can be drawn from this fact: First, the true 
microscopic affinity of the agonists to the resting state has to be rather low because 
the high efficacy increases the apparent affinity of the agonist. If the efficacy of ELIC 
activated with cysteamine is estimated to be 50, the resulting microscopic affinity of 
cysteamine to the resting state of ELIC would be as low as 15 to 20mM. Second, 
despite the low affinity of the agonists, the high open probability shows that 
cysteamine and propylamine are full and not partial agonists of ELIC. The 
identification of potent agonists confirmed that ELIC exhibits all major properties of 
eukaryotic receptors, which suggests that the conserved activation mechanism of the 
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family of pLGICs is also present in ELIC and that the protein is thus a valuable model 
system for the family. 
Properties of the open Pore 
The possibility to activate ELIC facilitated the investigation of its permeation 
properties. The quantification of the ion selectivity, based on the measurement of 
reversal potentials under asymmetric conditions, requires the control over both the 
intra- and extracellular solutions. This was achieved by using two different 
electrophysiological techniques, patch clamp and the recording of reconstituted ELIC 
in artificial bilayers. 
One of the striking features in the electrophysiological recordings of ELIC is the 
detection of single channel events upon agonist application. The single channel 
conductance of ELIC was determined to a value of about 80pS at physiological ion 
concentrations, which distinguishes the protein as fast conducting ion channel. The 
conductance of ELIC is higher than that of most known eukaryotic pLGICs. It is ten 
times higher than the 8pS conductance of GLIC (5) and it is in the same range as the 
85pS of the T.califonica AChR, the highest conducting member of the family (14). 
The large conductance facilitates the recording considerably and it makes ELIC a 
very good candidate for detailed single channel kinetic approaches. 
Single channel data was also used to determine the ion selectivity of ELIC, which can 
be measured with high accuracy, since the measurements are not influenced by 
endogenous channels and transporters in the cell membrane, or impurities carried 
along the purification and reconstitution procedure. Since the measured reversal 
potential at asymmetric conditions is at the Nernst-potential of the respective cation, 
ELIC was determined to be cation selective. In contrast to the strict discrimination for 
cations over anions, the channel did not show any selectivity among the different 
monovalent cations potassium, sodium and caesium. Divalent calcium ions are 
conducted though the pore as well, but their presence reduces the conductance of 
the channel. This effect is known from other cation selective pLGICs and was studied 
in detail for AChRs, 5HT3Rs and GLIC (45, 62, 95). Divalent cations are thought to 
interact stronger with the residues of the pore than monovalent cations and their 
conductance thus saturates at comparably low ion concentrations, whereas the 
conductance of monovalent cations increases linear without saturation. Due to their 
higher affinity, divalent cations dwell longer in the pore than monovalents and thereby 
reduce the total ion flux through the channel.  
The ion selectivity properties place ELIC in the cation selective branch of the family, 
with a large conductance for monovalent and divalent cations. All the facets of ion 
selectivity are strongly conserved within the cation selective pLGICs (96), consistent 
with the proposed similarity of the pore geometry and the conservation of the 
chemical properties of the pore lining residues, both constituting the main 
determinants of ion selectivity in pLGICs. 
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Structure determination of different states 
High resolution crystal structures of pLGICs in different functional states are required 
to understand the conformational changes involved in receptor function. Until today, 
all available structures of pLGICs have been determined in a single distinct state, a 
non-conductive state of ELIC and the conductive state of GLIC and GluCl. All 
attempts to crystallize the non-conductive state of GLIC and GluCl were so far 
unsuccessful. With known ELIC agonists, broad crystallization efforts were carried 
out to crystallize the ELIC-agonist complex. The goal was to determine its structure in 
another, either conducting or desensitized conformation. The crystals from several 
conditions were analyzed and their structures were determined, but none of them 
revealed any conformational differences compared to the initial structure. This may 
have several reasons: In most cases, a protein crystallizes in the conformation of the 
thermodynamically lowest energy state. This is the open conformation of GLIC and 
GluCl and a non-conducting conformation of ELIC. In the case of GluCl, the open 
state was stabilized with the agonist glutamate and the allosteric modulator 
ivermectin (13). GLIC is locked in the open conformation due to the low pH of the 
crystallization condition, since protons activate the channel. The open state might 
also be stabilized by protonation of a site in the transmembrane domain of GLIC 
which if protonated, stabilizes the open pore conformation by a modulatory effect 
similar to ivermectin in GluCl (97). In contrast to GLIC and GluCl, ELIC could not be 
crystallized in the active conformation. Electrophysiological measurements revealed 
that ELIC only transiently adopts an active conformation before entering a 
desensitized state. Therefore, the open state is thermodynamically not stable.  
The determined structures of ELIC in the apo form and the agonist complex did not 
reveal any appreciable conformational changes at the medium resolution data of the 
agonist complex. Liganded and unliganded structures show a non conductive state 
with an obstructed pore, even though the agonist was bound in its binding pocket. It 
is thus unclear if the structures show the resting state, which is stable in the absence 
of agonist, or the desensitized state, the most stable state with agonist bound. The 
underlying cause for this behavior could be that not all conformations of ELIC are 
accessible in the detergent solubilized state or that the crystal contacts stabilize the 
observed non-conducting conformation. All crystals, which diffracted to high 
resolution, were grown in conditions containing ammonium sulfate or barium acetate. 
Interestingly, it was impossible to detect the agonist in the ligand binding site in 
crystallization conditions containing ammonium ions and ligands were only visible in 
the electron density if the ammonium ions were replaced by sodium and lithium. This 
led to the speculation that ammonium may compete with the agonist for the binding 
pocket and thereby acts as a low affinity inhibitor which stabilizes the closed state. As 
Barium is also known to inhibit ELIC, it seems to be important to reach a certain 
degree of inhibition to stabilize the non-conducting state of ELIC and to produce well 
diffracting crystals. 
 
  
92 
Modulation of ELIC 
The modulation of pLGICs is a physiologically and pharmaceutically important effect 
on this family of receptors as many drugs or natural toxins work either by enhancing 
or inhibiting their function. Even though activating ligands for ELIC have only been 
available for a short time, two different modes of the inhibition of ELIC were 
discovered. The first is the competitive inhibition of ELIC by acetylcholine. The 
second is the allosteric inhibition of ELIC by divalent cations. These modulators show 
striking parallels to the known and well characterized modulators of eukaryotic 
receptors. In the context of ELIC, the functional investigation can be extended with 
structural studies, thus offering the possibility to explain the effects of these 
modulators truly on a molecular level. 
Inhibition by Acetylcholine 
ACh was shown to act as a competitive inhibitor of ELIC (98). It binds to the agonist 
binding site of ELIC with an affinity of 1.5mM which is clearly a higher affinity to the 
resting state than the identified agonists. This underlines again the allosteric behavior 
of ELIC, where agonists have a low affinity to the resting state but a high affinity to 
the active state, whereas ACh has a high affinity to the resting state and no 
measureable affinity to the active state, since the active conformation cannot be 
adopted if ACh is bound. The distinct effects of cysteamine and acetylcholine 
demonstrate that agonists and antagonists selectively stabilize different 
conformations of the receptor. 
Based on the various structures of AChBPs in complex with different agonists and 
antagonists it was found that all agonists are small molecules capable of activating 
the receptor. All antagonists were found to be big and bulky molecules ranging from 
alkaloids to small proteins. The proposed mechanism suggests that binding of these 
large molecules spreads the agonist binding site and inhibits the receptor activation 
by preventing C-loop capping (99). The competitive inhibition of ELIC by ACh seems 
to contradict the current view of competitive inhibition in pLGICs. ACh is not larger 
than the identified agonists for ELIC and the clear outward movement of the C-loop in 
the AChBP-antagonist complex is not visible in the ACh bound structure of ELIC. In 
contrary, even a contraction of the C-loop is observed. It is therefore not likely that 
ACh acts by a similar mechanism by preventing C-loop capping as both agonists and 
antagonists bind with a similar mode to the receptor. The binding pocket of ELIC 
including the conserved ring of aromatic amino acids responsible for the cation-π 
interaction can bind several different cations but seems to be able to differentiate 
between a positive charge of an amino- and a substituted amino group. 
It was also shown that 2-dimethylaminoethylacetate, an ACh derivate with a tertiary 
instead of a quaternary amine, could activate ELIC with low potency. The observed 
activation is much slower compared with cysteamine. Even though it is not known yet 
if the compound acts as a full or a partial agonist, it hints towards a gradual behavior 
ranging from the quaternary ammonium  compounds, which act as competitive 
antagonist, over the tertiary amines as partial agonist to the amines as full agonist. 
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Inhibition by divalent Cations 
In this thesis, I showed that ELIC is inhibited by divalent cations on the extracellular 
side. Divalent cations, such as calcium, magnesium and zinc, are known to modulate 
the function of pLGIC in a positive or negative way. Our study investigated the 
inhibitory effects of calcium ions on ELIC in detail and showed that other alkaline 
earth metal and zinc ions act at the same site and by the same allosteric mechanism 
of inhibition. Even though the phenotypes of the inhibition by ACh and divalent 
cations are similar, the underlying mechanisms are fundamentally different. 
Two effects of divalent cations on ELIC were observed. The first was a shift of the 
dose response curve to higher agonist concentrations in the presence of divalent 
cations. This effect did not saturate, even at high concentrations. Additionally, the 
maximal current decreased at higher concentrations of divalent cations. This 
reduction of the current could not be fully attributed to the lower conductance of ELIC 
in the presence of divalent cations. It shows in contrast to the shift of the dose 
response curve, that the inhibiting effect of divalent cations is not surmountable and 
thus cannot be caused by competitive inhibition. 
Three barium binding sites were identified in ELIC by exploiting the anomalous 
scattering properties of barium by X-ray crystallography. The functional relevance of 
these sites was probed in a mutagenic approach, which showed that two of these 
sites do not contribute to the inhibition by divalent cations. One of the binding sites, 
called Sout, was found to be solely responsible for the allosteric inhibition of ELIC by 
divalents. It is located in the dimer interface between adjacent subunits. Barium was 
found to interact with acidic residues of the Cys-loop and the F-loop. All tested 
divalents bind to this site with affinities close to the environmental concentration of 
calcium, magnesium and zinc, thus suggesting that the effect may be relevant at 
physiological conditions. The location of this inhibitory site in the dimer interface of 
the receptor, 15Å from the agonist binding site, is intriguing as the structural 
rearrangements in this region are believed to lead to receptor activation upon agonist 
binding. 
Divalent cations were found to allosterically inhibit ELIC by decreasing the efficacy of 
channel gating, not the affinity to the agonist. A four state kinetic model, which was 
proposed for eukaryotic receptors to explain the mechanism of partial agonists, can 
also explain all the observed effects of divalent cations on ELIC. The model consists 
of one agonist binding step and two gating steps, termed bind, flip and open. It was 
also used for the activation mechanism of ELIC, because only the model containing 
the flip-state allows the explanation of the different functional effects of divalent 
cations on ELIC activation. 
The binding step is not inhibited by divalent cations, because the inhibition would be 
completely surmountable in this case, which was not the case in our recordings. To 
probe an effect on the flipping step, agonist concentration jump experiments were 
performed at conditions where the flip transition is the rate limiting step in receptor 
activation. The maximal activation rate was equal, both in the absence and the 
  
94 
presence of calcium at concentrations which have a measurable effect on the dose 
response curve. This means that the flip transition is not inhibited by divalent cations, 
at least at low concentrations. Therefore, it has to be the opening step which is 
affected by divalent cations (Figure 16). 
  
Figure 16 Activation mechanism of ELIC in absence and presence of divalent cations. Upon agonist application, 
ELIC adopts different functional states homologous to the eukaryotic receptors termed the resting state, the 
agonist bound resting state, the flip-state and finally the open state. In the activation process, the flipping is the 
rate limiting step. In the presence of divalent cations bound to the allosteric binding site, the activation of ELIC is 
inhibited by reducing the rate of channel opening. 
There is still the possibility that the flip transition is also affected at higher calcium 
concentrations, but this hypothesis cannot be tested because the required agonist 
concentrations, to perform the concentration jump experiments, would become too 
high. 
Mechanism of inhibition 
A possible mechanism of inhibition can be deduced by comparing the structures of 
pLGIC in the open state, as seen in GLIC or GluCl, and ELIC in a non-conducting 
conformation. One of the most striking differences next to C-loop capping can be 
found in the F-loop. In GLIC and GluCl, the F-loop is tightly packed in the interior of 
the subunit interface, interacting with residues of both the principal and the 
complementary subunit. The F-loop in ELIC is larger compared to GLIC and GluCl 
and moved 5 to 10Å outwards, away from the core of the protein. Additionally, in all 
the structures of ELIC, the F-loop is not well resolved. This suggests that the F-loop 
of ELIC is intrinsically not well ordered and mobile, at least in the non-conductive 
state captured in the crystallization experiments. The divalent cations in their binding 
site Sout could prevent the movement of the F-loop of ELIC to adopt a GLIC or GluCl 
like open conformation and thereby impair channel gating. 
The inhibition of ELIC by divalent cations also offers insights into the activation 
mechanism. In the absence of divalent cations, the mutants of the site Sout show a 
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reduced apparent affinity to the agonists compared to the native receptor, indicating 
an impaired function of the receptor and the importance of this region for receptor 
activation. As already seen, divalents do not interfere with the microscopic affinity of 
the agonists and, as our results suggest, the flip conversion of ELIC is also not 
affected. Thus, the conformational change of the F-loop is not part of the flipping of 
the receptor but it might be truly involved in the opening step.  
From a structural point of view, it is unclear if the ELIC structures show the resting or 
a desensitized state. The functional characterization of the allosteric inhibition of 
ELIC shows that divalents act by stabilizing the resting state. In the performed 
experiments, the stabilization of the desensitized state would result in a shift of the 
dose response curve to lower agonist concentrations because the activation would 
not be affected but the maximal response would be reached faster due to the 
enhanced desensitization. Therefore, the results are compatible with the assumption 
that the structures of ELIC show a resting, not a desensitized state. 
Comparison to eukaryotic receptors 
The comparison of the allosteric inhibition of ELIC to the modulation of the eukaryotic 
receptors by divalent cations reveals striking similarities. The modulation in 
eukaryotic receptors can either be positive or negative but the identified residues that 
interact with divalent cations are located close to the Sout site of ELIC. The receptors 
that exhibit an inhibiting effect by divalent cations are 5HT3 and GABA receptors. The 
dose response curves of 5HT3 receptors shift to higher agonist concentrations in the 
presence of calcium, an effect very similar to ELIC, but the binding site is believed to 
be located at the extracellular mouth of the pore (82). GABA receptors are inhibited 
by zinc. It is unknown if zinc leads to a shift of the dose response because the effect 
was described by inhibition curves at a fixed agonist concentration (79). The 
identified residues interacting with zinc overlap with the Sout found in ELIC (Figure 
17). Even though the primary sequence of the loops, which contain the interacting 
residues, are not conserved, it underlines the importance of this region in the 
modulation of pLGICs and hints towards a conserved mechanism where divalent 
cations can stabilize either the resting or the active state by binding to a region 
related to Sout.  
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Figure 17 Comparison of the identified residues interacting with zinc in the GABA receptor (a) and different 
divalent cations in ELIC (b). The positions of the residues in the GABA receptor are modeled using a homology 
model based on the AChBP. In the GABA receptor, the identified histidine and glutamates coordinate zinc 
whereas the binding of divalent cations in ELIC only involves acidic amino acids. Despite the differences in the 
binding sites, both of them are located at similar positions in the subunit interface and could act by similar 
mechanisms. 
 
The stabilization of distinct functional states is a hallmark of the modulation of 
allosteric proteins. Next to the binding site of divalent cations, there are different 
binding sites for other allosteric modulators known in pLGICs, such as 
benzodiazepines or ivermectin. The binding site for benzodiazepines in 
heteropentameric GABARs is located in the extracellular domain, a site which is 
homologous to the agonist binding site but not involved in agonist binding. In 
contrast, Ivermectin binds to a site in the transmembrane domain. Both of them are 
positive modulators and act by stabilizing the open state. The binding of 
benzodiazepines shifts the population of receptors towards the flip state, thus 
increasing the apparent affinity of the agonist and facilitating receptor activation (66, 
73). The binding of ivemectin slightly changes the relative position of the 
transmembrane helixes to each other. It thereby stabilizes the pore in the open 
conformation. The stabilized open conformation of the pore acts via the allosteric 
network of the receptor also on the ligand binding domain, thus locking the whole 
receptor in the active state. This leads, analogous to the benzodiazepines, to an 
increase of the apparent affinity of the agonists and to facilitated receptor activation 
(13). 
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Figure 18 A ribbon representation of ELIC indicating the location of the binding sites of different molecules which 
act on pLGICs. Agonists and competitive antagonists act orthosteric in the agonist binding site, whereas 
benzodiazepines bind to a homologous site in the GABAR. Divalent cations bind to the newly identified binding 
site, located about 15Å from the agonist binding site. The ivermectin binding site is located in the transmembrane 
region of the invertebrate GluCl. All these molecules, independent of their effect, bind in the interface between the 
subunits, where they potently influence the conformational equilibrium of these allosteric receptors. 
Even though the functional effects are different, agonists, antagonists or modulators 
act by stabilizing a certain state in the activation mechanism. Interestingly, the 
different binding sites are located in the dimer interfaces between the subunits of the 
receptor (Figure 18). In allosteric proteins, such as pLGICs, the communication 
between the subunits is crucial for their function. Thus, it is not surprising that the 
modulators successfully act at this important interface to influence the function of 
these proteins. 
 
Physiological role of ELIC 
The physiological role of most ion channels in prokaryotes as well as the function of 
ELIC in its host Erwinia chrysanthemi is still unknown. The only exceptions are 
mechanosensitive channels which act as emergency valves to release osmolytes in 
case of osmotic stress. Other ion channels could be involved in a yet unknown 
response to environmental stress or in a novel signal transduction pathway. A role in 
chemotaxis is not likely because most of them are also found in the membranes of 
immotile bacteria. The energy production in bacteria relies on the electrochemical 
gradients of protons and sodium which are closely linked to the membrane potential. 
Similar to animal cells, the resting potential of prokaryotes is mainly determined by 
their potassium gradient. The intracellular potassium concentration is 300 to 700mM 
resulting in a very negative resting potential of -120 to -200mV, indicating its 
importance for the electrochemical driving force of protons and sodium (100). 
Bacteria are small cells and the capacity of their membrane is therefore very small as 
well and the movement of only a few ions can already change the membrane 
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potential substantially. Ion channels in bacteria must therefore be tightly shut and 
should open only transiently. 
The electrochemical requirements of prokaryotes offer two potential functions for 
ELIC. The protein could be involved in electrical signaling similar to neurotransmitter 
receptors in animals. It was shown in E.coli that the membrane potential of bacteria is 
variable and even highly dynamic. Next to providing the major driving force for energy 
production, membrane transport and flagellar motility, it could therefore also be 
involved in signaling processes (101). This signal transmission pathway is only 
known from the nervous systems of animals and was never observed in prokaryotes. 
The second possibility could be a role in restoring the negative membrane potential 
by potassium efflux, if the cell was depolarized before by proton or sodium influx. 
One of the identified agonists of ELIC, GABA, is not only a neurotransmitter in 
animals but also produced and exported by bacteria upon acid stress. In the genome 
of E.chrysanthemi, the ELIC gene is located in an operon with two other genes. One 
of them is coding for a putative glutamate decarboxylase, the other for a transporter 
of the MFS family. This makes GABA a likely candidate for the natural agonist of 
ELIC, which is produced and transported to the periplasm by the host cell. 
Alternatively, the agonist could also be an external signal. Plants produce GABA as 
well and secret it if the plant was wounded. Plant wounds are natural habitats of the 
plant pathogen E.chrysanthemi and offer a high concentration of nutrients. Both acid 
stress and the cotransport of nutrients with sodium lead to an increased influx of 
positive charges and thereby decrease the membrane potential. The activation of 
ELIC could then quickly restore the membrane potential, much faster than ion pumps 
which are used to establish the electrochemical gradient. 
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Conclusions 
In this thesis I have described the work leading to the identification of agonists for 
ELIC. This has allowed me to carry out a study about the mechanisms of activation 
and allosteric inhibition of this receptor using both functional and structural methods. 
The functional characterization revealed a high degree of conservation compared to 
eukaryotic pLGICs. The agonist binding properties of ELIC are highly similar to GlyRs 
and GABARs whereas the ion selectivity places ELIC in the branch of the cation 
selective pLGICs, together with AChRs and 5HT3Rs. Next to activation, the 
mechanism of the allosteric modulation of ELIC by divalent cations could be resolved. 
This modulation, which is known from eukaryotic receptors, is assumed to play an 
important role in the regulation of the synaptic activity in the nervous system. The 
discovery of the inhibitory effect of divalent cations on ELIC is also important for 
future studies on ELIC, as care has to be taken on the concentration of divalent 
cations used in the experiments, to make the results from different research groups 
comparable. 
Due to the structural and functional resemblance between ELIC and eukaryotic 
receptors, it is very likely that the main mechanisms of receptor activation are 
conserved. Any observation made in ELIC, and the mechanisms deduced from its 
behavior will thus likely extend to the whole family of pLGICs. 
Since we know the high resolution structures of three pLGICs, ELIC is not the only 
pLGIC which allows detailed studies on structure-function on the same protein. 
However, the use of ELIC as a model system offers certain advantages over the 
other receptors with available structures. Compared to GLIC, ELIC is a true ligand-
gated ion channel with small molecules as agonists, whereas GLIC senses its own 
protonation state to trigger activation. From an experimental view, ELIC does not 
require pH-jumps which can lead to artifacts in the measurements and undesired side 
effects in the cells used for expression. GluCl is a eukaryotic receptor with the 
highest similarity to the human receptors of pharmaceutical interest. However, the 
construct of GluCl, which was used for crystallization, is a homopentamer of the α-
subunit which does probably not exist in the host organism C.elegans, as the native 
receptor is a heteropentamer formed by α and β subunits. Due to the artificial subunit 
composition, GluCl cannot be activated solely by its agonist glutamate, but 
additionally requires ivermectin for activation, which limits the impact of functional 
experiments. Moreover, since ELIC has the highest single channel conduction of all 
the receptors of known high-resolution structure, it is most suitable for kinetic 
investigations on a single channel level. The functional properties of ELIC, together 
with the possibility to produce high resolution structures, thus make it an attractive 
model system to elucidate the molecular mechanisms underlying the function of 
pLGICs.  
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Outlook 
All the high resolution crystal structures of pLGICs were determined in a single 
functional state. However, the structure determination of different states of the same 
receptor, which is crucial to understand receptor function, has not been achieved. 
One of the main future goals will thus be the crystallization of ELIC in a conducting 
conformation, even though this state is only transient in the native receptor. To 
overcome this problem, a mutagenic approach could be used to stabilize the receptor 
in the open conformation and to prevent desensitization. Additionally, the introduction 
of cysteines at specific positions could be used to establish intra- or intermolecular 
crosslinks to trap the open conformation. Another attempt could involve allosteric 
modulators. Similar to ivermectin in the case of GluCl, a positive allosteric modulator 
could stabilize ELIC in the open conformation. Unfortunately, such potent modulators 
of ELIC have not yet been identified. 
The open conformation of ELIC would certainly increase the understanding of the 
function of pLGICs, but since any structure only provides a static picture, the 
activation mechanism and the sequence of the conformational rearrangements 
necessary to reach the conducting state would still have to be explored. Thus next to 
the structure determination of different functional states, functional experiments 
focusing on ligand recognition, the interface between the extracellular and 
transmembrane domain and the pore are needed. Due to the high single channel 
conductance, a detailed kinetic mechanism could be deduced from single channel 
measurements and the effect of mutations in certain regions of the receptor could 
directly be linked to the affected step in the activation mechanism. Other methods 
such as voltage clamp fluorimetry could be used to study the conformational changes 
of the extracellular domain simultaneously with the current elicited by the ion channel 
in the open state. The present studies offer only an initial view on the complex 
mechanisms that will have to be explored in detail in future studies. 
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Appendix A 
 
Abbreviations 
LGIC Ligand-Gated Ion Channel 
pLGIC pentameric Ligand-Gated Ion Channel 
ACh acetylcholine 
5HT 5-hydroxytryptamine, or serotonin 
Gly glycine 
GABA γ-amino butyric acid 
ELIC Erwinia chrysanthemi Ligand-Gated Ion Channel 
GLIC Gloebacter violaceus Ligand-Gated Ion Channel 
SCAM substituted cysteine accessibility method 
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